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2 LIST OF ABBREVIATIONS 
AGO2  argonaute 2 
AKAP12 A-kinase anchoring protein 12 
AML  acute myeloid leukaemia 
AML-MRC acute myeloid leukaemia with myelodysplasia-related changes 
BM   bone marrow 
CDR  commonly deleted region 
CEBPA  CCAAT enhancer binding protein alpha, transcription factor 
CLL  chronic lymphocytic leukaemia 
CPX-351 liposomal daunorubicin-cytarabine 
CR  complete remission 
c-FOS  proto-oncogene, the human homolog of the retroviral oncogene v-FOS 
c-MYB  avian myeloblastosis virus oncogene cellular homolog 
ddPCR  droplet digital PCR 
DRAM1  damage regulator autophagy modulator 1 
ECM  extracellular matrix 
ERK1 extracellular signal-regulated kinase 1, also known as mitogen-activated protein 
kinase 3 (MAPK3) 
ERK2 extracellular signal-regulated kinase 2, also known as mitogen-activated protein 
kinase 1 (MAPK1) 
EVs  extracellular vesicles 
FLI1  friend leukaemia virus integration 1 transcription factor 
HDL  high density lipoproteins 
HI  haematologic improvement 
HSCs  haematopoietic stem cells 
HSCT  haematopoietic stem cell transplantation 
HSPCs  haematopoietic stem/progenitor cells 
IHBT  Institute of Hematology and Blood Transfusion 
lncRNAs long noncoding RNAs 
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MCL1  myeloid cell leukaemia sequence 1 
mCR  marrow complete response 
MDS  myelodysplastic syndromes 
MDS-EB  MDS with excess blasts  
MDS-MLD MDS with multilineage dysplasia 
MDS-RS  MDS with ring sideroblasts 
MDS-SLD MDS with single lineage dysplasia 
MDS-U  MDS unclassifiable 
miRNAs microRNAs 
mtDNA  mitochondrial DNA 
MTHFD2 methylenetetrahydrofolate dehydrogenase 2 
NF-κB   nuclear factor-κB 
NGS  next generation sequencing 
NPM1  nucleophosmin 1 
ORR  overall response rate 
OS  overall survival 
PB  peripheral blood 
PD  progressed disease 
PFS  progression-free survival 
piRNAs  piwi-interacting RNAs 
PR  partial remission 
PTEN  tumour supressor, phosphatase and tensin homologue deleted on chromosome 10 
PUS7  pseudouridine synthase 7 
qPCR  quantitative PCR 
RA  refractory anaemia 
RAEB  refractory anaemia with excess blasts 
RARS  refractory anaemia with ring sideroblasts 
RCMD  refractory cytopenia with multilineage dysplasia 
RCUD  refractory cytopenia with unilineage dysplasia 
RISC  RNA-induced silencing complex 
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RN  refractory neutropenia 
RPS14  ribosomal protein S14 
RT  refractory thrombocytopenia 
RT-qPCR  reverse transcription quantitative PCR 
SD  stable disease 
siRNAs  small interfering RNAs 
SMAD7  mothers against decapentaplegic homolog 7 
sncRNAs small noncoding RNAs 
snoRNAs small nucleolar RNAs 
snRNAs  small nuclear RNAs 
TET2  tet methylcytosine dioxygenase 2 
TGF-β  transforming growth factor β 
TIRAP  toll-interleukin-1 receptor domain-containing adaptor protein 
TNF-α  tumour necrosis factor α 
TRAF6  tumour necrosis factor receptor-associated factor-6 
tRNAs  transfer RNAs 
tsRNAs  tRNA-derived small RNAs  
TWIST1  twist basic helix-loop-helix transcription factor 1 
 




Myelodysplastic syndromes (MDS) are a heterogeneous group of bone marrow (BM) disorders 
characterized by ineffective haematopoiesis, BM dysplasia, and peripheral blood cytopenia. In recent 
years, substantial progress has been made towards understanding the molecular pathogenesis 
of MDS that has brought new possibilities in MDS diagnostics, prognostics, and treatment.  
Small noncoding RNAs (sncRNAs), especially microRNAs (miRNAs), are in the field of scientific interest 
in terms of their expression, function, role in disease development, and potential utilization 
as disease biomarkers. Special attention has been focused on extracellular sncRNAs present in blood 
circulation, so called ‘circulating’ sncRNAs, which may become easily accessible biomarkers of disease 
state or risk of progression. 
We have conducted several studies on intracellular and extracellular sncRNA profiles of CD34+ BM 
cells and blood plasma, respectively, from MDS patients using microarrays or next generation 
sequencing (NGS). We aimed to identify specific sncRNA profiles associated with MDS and search 
for sncRNA biomarkers predictive of the patient prognosis and response to treatment 
with azacitidine (AZA). Another goal was to characterize and compare circulating sncRNA profiles 
of two different extracellular materials, total plasma and plasma-derived extracellular vesicles (EVs), 
in order to determine their usefulness as sources of MDS biomarkers. 
Initially, using microarrays, we identified significantly lower levels of miR-27a-3p, miR-199a-5p, 
and miR-223-3p in total plasma of higher-risk MDS patients compared to lower-risk MDS patients. 
Further analyses indicated that the low levels of miR-223-3p and miR-451 are associated 
with unfavourable overall survival (OS) and progression-free survival, respectively.  
Using NGS, we found other deregulated sncRNAs, including non-miRNA species, between early 
and advanced stages of MDS. We observed increased levels of many circulating miRNAs related 
to haematopoiesis (e. g. miR-103a-3p, miR-103b, miR-107, miR-221-3p, miR-221-5p, and miR-130b-
5p) and miRNAs located in chromosomal region 14q32 (e.g. miR-127-3p, miR-154-5p, miR-323b-3p, 
miR-382-3p, miR-409-5p, and miR-485-3p) in early MDS compared to advanced MDS. 
We defined a signature of four sncRNAs (miR-1237-3p, U33, hsa_piR_019420, and miR-548av-5p) 
whose EV levels were the most significantly associated with OS. Further, a combined score of five 
plasma miRNAs (miR-423-5p, miR-126-3p, miR-151a-3p, miR-125a-5p, and miR-199a-3p) was 
determined as a predictor of response to AZA treatment. In CD34+ BM cells, the high level  
of miR-17-3p and low levels of miR-100-5p and miR-133b before treatment were associated 
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with favourable overall response rate to AZA therapy. Moreover, miR-100-5p was found 
as a predictor of survival, its low level before treatment associated with favourable OS in AZA treated 
patients. 
Regarding the two extracellular materials, total plasma and EVs, hierarchical cluster analysis showed 
that RNA content of EV samples is more homogeneous than that of total plasma samples. Further, 
substantially higher number of deregulated sncRNAs between these two materials was found in MDS 
patients than in control counterparts. 
In conclusion, our results demonstrate distinct sncRNA profiles in total plasma, EVs, and CD34+ cells 
of MDS patients. These profiles are specific for distinct MDS stages and may predict patient outcome. 
We identified several sncRNAs, mostly miRNAs, that are associated with patient survival 
and response to AZA therapy and thus, may be considered as potential biomarkers of the disease.  
 




Myelodysplastický syndrom (MDS) je heterogenní onemocnění vyznačující se nedostatečnou 
krvetvorbou, dysplazií kostní dřeně a cytopenií jedné nebo více krevních řad v periferní krvi. Současný 
pokrok v porozumění patogenezi MDS na molekulární úrovni přináší nové možnosti v oblasti 
stanovení diagnózy, prognózy a léčby tohoto onemocnění. 
Malé nekódující RNA (sncRNA), obzvláště mikroRNA (miRNA), jsou středem zájmu v oblasti výzkumu 
jejich funkce, exprese, úlohy při vzniku a vývoji onemocnění a také jejich možného využití coby 
biomarkerů onemocnění. V poslední době je pozornost věnována také extracelulárním sncRNA a to 
obzvláště těm, které jsou přítomny v krevním oběhu, tzv. „cirkulujícím“ sncRNA. Cirkulující sncRNA 
jsou považovány za snadno dostupné potenciální biomarkery stavu onemocnění a rizika progrese. 
Základem této disertační práce je několik studií zabývajících se profily sncRNA u MDS pacientů. 
V rámci těchto studií jsme vyšetřovali jak profily intracelulárních sncRNA z CD34+ buňek kostní dřeně, 
tak profily extracelulárních sncRNA z celkové krevní plasmy a z extracelulárních vesikulů 
vyizolovaných z plasmy. K analýze jsme využili tzv. „high-throughput“ technologie, konkrétně 
microarrays a sekvenování nové generace (NGS). Cílem bylo určit profily sncRNA charakterizující MDS 
a nalézt konkrétní molekuly, které by byly schopné předpovědět další vývoj onemocnění a kvalitu 
odpovědi na léčbu azacitidinem (AZA). Také jsme porovnali profily cirkulujících sncRNA ze dvou 
extracelulárních materiálů (tj. z celkové plasmy a extracelulárních vesikulů) s cílem zjistit, jestli jsou 
vhodnými zdroji sncRNA biomarkerů pro MDS. 
Pomocí microarrays jsme nalezli významně snížené hladiny miR-27a-3p, miR-199a-5p a miR-223-3p 
v celkové plasmě pacientů s vysokorizikovým MDS oproti pacientům s nízkorizikovým MDS. Další 
analýzy ukázaly, že nízká hladina miR-223-3p předpovídá kratší dobu celkového přežití, zatímco nízká 
hladina miR-451 naznačuje kratší dobu do progrese onemocnění. 
Pomocí NGS jsme nalezli další sncRNA s odlišnými hladinami mezi pacienty s časnými a pokročilými 
stadii MDS. Kromě miRNA jsme zachytili i jiné druhy sncRNA. U pacientů s pokročilejšími stadii MDS 
jsme pozorovali zvýšené hladiny mnoha cirkulujících miRNA, které se účastní regulace krvetvorby 
(např. miR-103a-3p, miR-103b, miR-107, miR-221-3p,miR-221-5p a miR-130b-5p) a také miRNA 
lokalizovaných v chromosomální oblasti 14q32 (např. miR-127-3p, miR-154-5p, miR-323b-3p,  
miR-382-3p, miR-409-5p a miR-485-3p). 
Identifikovali jsme čtyři sncRNA (miR-1237-3p, U33, hsa_piR_019420 a miR-548av-5p), jejichž 
kombinované skóre vypočtené z naměřených hladin v extracelulárních vesikulech má spojitost 
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s trváním celkového přežití pacientů. Dále jsme určili pět miRNA (miR-423-5p, miR-126-3p,  
miR-151a-3p, miR-125a-5p a miR-199a-3p) z celkové plasmy, jejichž kombinované skóre předpovídá 
kvalitu odpovědi na léčbu AZA. V CD34+ buňkách kostní dřeně jsme pozorovali, že vysoká hladina 
miR-17-3p a nízké hladiny miR-100-5p a miR-133-b stanovené u pacientů před léčbou AZA ukazují 
na příznivou odpověď pacientů na tuto léčbu. Nízká hladina miR-100-5p před léčbou AZA navíc 
naznačuje delší celkové přežití léčených pacientů. 
Co se týče porovnání dvou extracelulárních materiálů, tj. celkové plasmy a extracelulárních vesikulů, 
klastrovací analýza ukázala, že obsah RNA je více homogenní u vzorků extracelulárních vesikulů 
oproti vzorkům celkové plasmy. Dále jsme zaznamenali podstatně více sncRNA s odlišnými hladinami 
mezi těmito dvěma materiály u MDS pacientů oproti zdravým jedincům. 
Z našich výsledků vyplývá, že celková plasma, extracelulární vesikuly izolované z plasmy a CD34+ 
buňky kostní dřeně MDS pacientů mají rozdílné profily sncRNA. Tyto profily jsou specifické pro různá 
stadia MDS a mohou předpovídat další vývoj onemocnění. Určili jsme několik sncRNA, většinou 
miRNA, jejichž deregulované hladiny souvisí s přežitím pacientů a odpovědí na léčbu AZA. Tyto 
sncRNA tedy mohou být považovány za potenciální biomarkery předpovídající další vývoj 
onemocnění u pacientů s MDS. 
 




Myelodysplastic syndromes (MDS) are a group of bone marrow (BM) disorders characterized 
by ineffective haematopoiesis leading to low numbers of mature blood cells. Substantial progress 
in understanding of MDS pathogenesis has been made in recent years. A vast literature has emerged 
regarding the spectrum of cytogenetic abnormalities, gene mutations, epigenetic modifications, gene 
expression patterns, and signalling pathways associated with the disease.  
Small noncoding RNAs (sncRNAs) include various species of endogenous RNAs. They are implicated 
in regulation of essential cellular processes. Cumulative evidence has shown that sncRNAs represent 
important regulators of haematopoiesis and their deregulation is also implicated in the pathogenesis 
of MDS. Generally, sncRNAs are considered to be potentially promising molecular biomarkers 
of disease development. 
We performed a comprehensive analysis of sncRNA profiles in all MDS subtypes and searched 
for sncRNAs with specific expression patterns that may be of clinical relevance in terms 
of diagnostics, prognostics, and prediction of treatment response. These sncRNAs as auxiliary 
biomarkers may contribute to better disease and therapy management, prediction of patient 
outcome, and prevention of the burden associated with ineffective drug application. 
The improvement in all these aspects would support a personalized approach to the MDS patients. 
The analyses were performed on different materials, i.e. CD34+ BM progenitor cells and blood 
plasma. The CD34+ cells are pivotal in the MDS pathogenesis and provide insight into the complete 
transcriptome of cellular sncRNAs specific for the disease. Identification of deregulated sncRNAs 
in the CD34+ cell population may reveal other factors contributing to the disease development 
or progression. However, the aspiration of BM is an invasive process carrying a risk of complication, 
such as persistent bleeding and infection. Thus, less invasive approach for continuous monitoring 
of patient condition would be beneficial. Extracellular sncRNAs circulating in blood (so called 
‘circulating’ sncRNAs) meet this requirement and have become the centre of interest in the field 
of noninvasive biomarkers. In this context, we analysed circulating sncRNA profiles in different 
fractions of blood, i.e. total blood plasma and separated extracellular vesicles (EVs) circulating 
in plasma. It is the very first study comparing sncRNA profiles in paired samples of the two 
extracellular materials (total plasma and EVs) in MDS.  
For investigation, we used high-throughput technologies, specifically microarrays and next 
generation sequencing (NGS). The initial studies were performed by microarray profiling, enabling 
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detection of thousands of sncRNA transcripts limited only to known sequences provided 
by databases (predominantly microRNAs). In the most recent study, due to easier access, we have 
employed the NGS technology, allowing the capture of complete range of RNA transcripts present 
in a sample and identification of novel sncRNA molecules. Together with the advantage of its wide 
dynamic range, NGS provides a global view on the complexity of sncRNA patterns and a deeper 
insight into the molecular background of MDS. 
This thesis summarizes the results from three publications (listed below), which analyse sncRNA 
profiles across MDS subtypes in BM cells, total plasma, and plasma-derived EVs. The thesis provides 
the novel data on sncRNAs in MDS, and explores the possibility of utilizing sncRNAs as molecular 
biomarkers of MDS. 
 
Publications that underlie this thesis 
This thesis is based on the following publications. They are listed in such order that keeps 
the continuity of the thesis, not according to the year they were published. In the text they are 
referred to as P1, P2, and P3 for Publication 1, Publication 2, and Publication 3, respectively. 
 
Publication 1 
Dostalova Merkerova M, Hrustincova A, Krejcik Z, Votavova H, Ratajova E, Cermak J, 
Belickova M. Microarray profiling defines circulating microRNAs associated 
with myelodysplastic syndromes. Neoplasma. 2017;64(4):571–8. PMID: 28485163 
Publication 2 
Hrustincova A, Krejcik Z, Kundrat D, Szikszai K, Belickova M, Pecherkova P, Klema J, Vesela J, 
Hruba M, Cermak J, Hrdinova T, Krijt M, Valka J, Jonasova A, Dostalova Merkerova M. 
Circulating Small Noncoding RNAs Have Specific Expression Patterns in Plasma 
and Extracellular Vesicles in Myelodysplastic Syndromes and Are Predictive of Patient 
Outcome. Cells. 2020 Mar 26;9(4):794. PMID: 32224889 
Publication 3 
Krejcik Z, Belickova M, Hrustincova A, Votavova H, Jonasova A, Cermak J, Dyr J E, Dostalova 
Merkerova M. MicroRNA profiles as predictive markers of response to azacitidine therapy 
in myelodysplastic syndromes and acute myeloid leukemia. Cancer Biomarkers. 
2018;22(1):101–10. PMID: 29630523 




The term ‘sncRNAs’ used in this thesis stands for multiple sncRNA species (e.g. miRNAs, piRNAs, 
and tsRNAs), which are described in the Introduction. Actually, most of the information and results 
in this thesis cover only miRNAs, because miRNAs are the species that have opened a new 
perspective on noncoding RNA functions and have been exclusively studied up to recently. 
Due to NGS, data on other sncRNA species have emerged and these species have also become 
of scientific interest. Some of our results include data on other sncRNA species and they 
are introduced and discussed as well. Thus, for simplification, the general term ‘sncRNAs’ is used 
throughout the thesis when appropriate. 
 




7.1 Myelodysplastic syndromes 
MDS are a heterogeneous group of clonal disorders of haematopoietic stem cells (HSCs) and their 
microenvironment, characterized by ineffective haematopoiesis, and manifested by BM dysplasia 
and peripheral cytopenia in one or more lineages. The incidence ranges from 3 to 4 per 100,000 
per year and increases with age. Rates per 100,000 per year in older patients increase from 7 in those 
aged 60 to 69 years to 35 in those aged over 80 years (1). MDS carry considerable risk 
of transformation to acute myeloid leukaemia (AML). On average, 30 percent of MDS patients 
develop AML during the course of the disease (2). 
 
7.1.1 Pathogenesis 
MDS are clonal disorders of HSCs caused by various genetic abnormalities. Chromosomal aberrations, 
gene mutations, copy number alterations, and abnormal gene expression are common in MDS. 
The initial abnormality leads to the formation of a pathological HSC clone with a certain growth 
advantage over its normal counterparts, resulting in a clonal haematopoiesis in BM. Increased 
genome instability of the abnormal HSC clone leads to acquisition of further aberrations. Additional 
abnormal clones can appear during the disease course and are associated with worsening conditions 
(3). 
Cytogenetic abnormalities are present in 35 to 50 percent of de novo MDS cases (4). It is well 
established that they are very heterogeneous in MDS. The most frequent chromosomal 
abnormalities in MDS are del(5q), del(7q)/-7, +8, del(11q), del(12p), del(17p), del(20q), and -Y (5). 
Hundreds of rare cytogenetic abnormalities have been reported in MDS, including for example 3q 
abnormalities, +13/del(13q), i(17q), +21/–21, and –X (6). Importantly, cytogenetic patterns are not 
stable in MDS, and a substantial number of patients acquire additional cytogenetic aberrations 
during the course of the disease, worsening the prognosis and increasing the risk of transformation 
to AML (7). 
Gene mutations participating in the MDS pathogenesis and progression affect RNA splicing 
machinery, DNA methylation, histone modifications, transcription factors, signal transduction 
proteins, and components of the cohesion complex. Mutations in RNA splicing and DNA methylation 
  INTRODUCTION 
18 
 
genes occur early and are considered founding mutations, whereas others that occur later are 
regarded as subclonal mutations (8).  
In MDS, the malignant cellular population with impaired ability to differentiate (9) rapidly expands, 
however hyperproliferation is accompanied by excessive apoptosis (10,11). This leads to insufficient 
peripheral blood (PB) cell count, i.e. cytopenia, in one or more lineages (anaemia, thrombocytopenia, 
and neutropenia) that is variable in degree and combination depending on the lineages most 
affected by increased levels of apoptosis. The discrepancy between hyperproliferation in BM and 
cytopenias in PB is the characteristic feature of early MDS. During MDS progression, the induction 
of apoptosis is decreased (12,13), resulting in gradual increase of blast number in BM and often 
transformation towards AML.  
Previous studies reported that AML evolves from an ancestral MDS subclone that acquires further 
genetic mutations mostly in a linear and hierarchical manner (14,15). Recent results by Chen et al. 
(16), however, suggest a model of non-linear clonal evolution arising from the stem cell level. 
Accumulation of mutations in stem cell compartments gives rise to a highly diverse subclonal 
architecture in MDS stem cells. Certain subclones provide a shared basis for both MDS development 
as well as AML transformation. Formation of MDS blasts or AML stem cell is then driven by different 
additional mutations in a non-linear and rather parallel manner (16).  
Further, chronic inflammation plays a critical role in the MDS pathogenesis and may act as a trigger 
of MDS development (17). The inflammatory signalling within the BM microenvironment may drive 
the functional repression of normal HSCs and subsequently the induction, selection, and expansion 
of mutant clones that are likely to malignant transformation. This indicates that MDS should be 
considered a disease of tissue rather than a disease of haematopoietic cells in isolation (18). 
 
7.1.2 Diagnosis and classification 
The risk of MDS increases with advancing age. The typical age at diagnosis of MDS is between 60 and 
75 years. Diagnoses are rare in adults under 50 years and children. Males are slightly more commonly 
affected than females. Clinical presentation of MDS is nonspecific and varies considerably depending 
on subtypes and severity of cytopenias. Symptoms are connected to the most affected cell lineages 
and may include fatigue, weakness, pallor (secondary to anaemia), infections and fever (secondary 
to neutropenia), and increased bleeding and bruising (secondary to thrombocytopenia). 
The diagnosis is generally suspected based on the presence of an abnormal complete blood count 
and is confirmed by performing BM aspiration and biopsy demonstrating morphological evidence 
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of dysplasia. A number of additional tests, including cytogenetics, flow cytometry and molecular 
genetics, are needed to complete the laboratory evaluation of patients with MDS (19). Dysplastic 
changes are the most important diagnostic features of MDS. A BM cell lineage is considered picture 
of MDS if more than ten percent of cells are affected. Cytogenetic examination of BM aspirate plays 
a key role in determining clonality of cells (20). In the appropriate clinical context, some cytogenetic 
abnormalities are sufficient evidence to determine MDS diagnosis. In addition, cytogenetics is also 
an important tool to assess prognosis and to choose the most effective form of therapy (4). 
MDS are very heterogeneous group of disorders with substantial diversity of conditions across 
the entire spectrum of MDS. Moreover, the boundaries between MDS and related myeloid disorders 
can be vague and difficult to characterize (21). To improve the specificity of the diagnosis 
and prognosis, classification systems have been developed. 
According to the World Health Organization (WHO), MDS subtype classification is based 
on determination of the blast cell percentage in BM and PB, PB cytopenias, presence or absence 
of ringed sideroblasts in BM (sideroblasts are erythroblasts with iron-loaded mitochondria found 
exclusively in pathological conditions (22)), presence of specific chromosomal abnormalities, 
and cytogenetic detection of del(5q). The most emphasized criteria for classification are the degree 
of dysplasia and blast percentages, whereas specific cytopenias have only minor impact on MDS 
classification. The WHO classification guidelines from 2008 (23) define following MDS subtypes: 
refractory cytopenia with unilineage dysplasia (RCUD, comprising refractory anaemia (RA), refractory 
neutropenia (RN), and refractory thrombocytopenia (RT)), refractory anaemia with ring sideroblasts 
(RARS), refractory cytopenia with multilineage dysplasia (RCMD), refractory anaemia with excess 
blasts 1 and 2 (RAEB-1, RAEB-2), MDS with isolated del(5q), and MDS unclassifiable (MDS-U). 
The subtypes are described in Table 1 (23). The last edition of the WHO classification guidelines 
from 2016 (24) refines MDS subtypes as follows: MDS with single lineage dysplasia (MDS-SLD), MDS 
with multilineage dysplasia (MDS-MLD), MDS with ring sideroblasts (MDS-RS), MDS with excess 
blasts (MDS-EB), MDS with isolated del(5q), and MDS unclassifiable (MDS-U). The subtypes are 
described in Table 2 (24).  
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Table 1. MDS classification according to the WHO guidelines from 2008 (23). Peripheral blood (PB) 
and bone marrow (BM) findings in particular MDS subtypes. 
MDS subtype PB findings BM findings 
Refractory cytopenia with 
unilineage dysplasia (RCUD):  
refractory anaemia (RA),  
refractory neutropenia (RN), 
refractory 
thrombocytopenia (RT)  
Unicytopenia or 
bicytopenia*1, no or rare 
blasts (< 1 %)*2 
Unilineage dysplasia: ≥ 10 % of the 
cells in one myeloid lineage, < 5 % 
blasts, < 15 % of erythroid precursors 
are ring sideroblasts  
Refractory anaemia with 
ring sideroblasts (RARS)  Anaemia, no blasts  
≥ 15 % of erythroid precursors are 
ring sideroblasts, erythroid dysplasia 
only, < 5 % blasts  
Refractory cytopenia with 
multilineage dysplasia 
(RCMD)  
Cytopenia(s), no or rare 
blasts (< 1 %)*2, no Auer 
rods*3,  
< 1 × 109/l monocytes  
Dysplasia in ≥ 10 % of the cells in two 
or more myeloid lineages (neutrophil 
and/or erythroid precursors and/or 
megakaryocytes), < 5 % blasts in BM, 
no Auer rods, ± 15 % ring 
sideroblasts  
MDS with isolated del(5q) 
Anaemia, usually normal 
or increased platelet 
count, no or rare blasts  
(< 1 %)  
Normal to increased megakaryocytes 
with hypolobated nuclei, < 5 % blasts, 
isolated del(5q) cytogenetic 
abnormality, no Auer rods  
Refractory anaemia 
with excess blasts-1  
(RAEB-1)  
Cytopenia(s), < 5 % 
blasts*2, no Auer rods,  
< 1 × 109/l monocytes  
Unilineage or multilineage dysplasia, 
5 %-9 % blasts*2, no Auer rods  
Refractory anaemia 
with excess blasts-2  
(RAEB-2)  
Cytopenia(s), 5 %-19 % 
blasts*4, Auer rods 
present or not*4,  
< 1 × 109/l monocytes  
Unilineage or multilineage dysplasia, 
10 %-19 % blasts*4, Auer rods present 
or not*4  
MDS unclassifiable (MDS-U)  Cytopenias,  
< 1 % blasts*2  
Unequivocal dysplasia in < 10 % of 
cells in one or more myeloid lineages 
when accompanied by a cytogenetic 
abnormality considered as 
presumptive evidence for a diagnosis 
of MDS, < 5 % blasts  
*1 Bicytopenia may occasionally be observed. Cases with pancytopenia should be classified  
as MDS-U. 
*2 If the BM blast percentage is < 5 % but there are 2-4 % blasts in PB, the diagnostic classification 
is RAEB-1. Cases of RCUD and RCMD with 1 % blasts in PB should be classified as MDS-U. 
*3 Rod‐shaped inclusions formed by crystallisation of cytoplasmic azurophilic granules (25). 
*4 Cases with Auer rods and < 5 % blasts in PB and < 10 % in BM should be classified as RAEB-2. 
Although the finding of 5-19 % blasts in PB is diagnostic of RAEB-2, cases of RAEB-2 may have < 5 % 
blasts in PB if they have Auer rods or 10-19 % blasts in BM or both. Similarly, cases of RAEB-2 may 
have < 10 % blasts in BM but may be diagnosed by the other two findings, Auer rods and/or 5-19 % 
blasts in PB. 
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Table 2. MDS classification according to the WHO guidelines from 2016 (24). Peripheral blood (PB) 
and bone marrow (BM) findings and cytogenetics in particular MDS subtypes. 
MDS subtype Dysplastic 
lineages Cytopenias*
1 
Ring sideroblasts  
as % of BM 
erythroid 
elements 







MDS with single 
lineage dysplasia 
(MDS-SLD)  
1  1 or 2  < 15 %/< 5 %*2 
BM < 5 %,  













2 or 3  1-3  < 15 %/< 5 %*2  
BM < 5 %,  
PB < 1 %,  







MDS with ring 
sideroblasts  
(MDS-RS)  





1  1 or 2  ≥ 15 %/ ≥ 5 %*2  
BM < 5 %,  
PB < 1 %,  











2 or 3  1-3  ≥ 15 %/ ≥ 5 %*2  
BM <5 %, PB 
<1 %,  








isolated del(5q)  1-3  1-2  None or any  
BM < 5 %,  
PB < 1 %,  
no Auer rods  
del(5q) alone 
or with 1 
additional 
abnormality 













MDS subtype Dysplastic 
lineages Cytopenias*
1 
Ring sideroblasts  
as % of BM 
erythroid 
elements 







MDS with excess 
blasts (MDS-EB)            
MDS-EB-1  0-3  1-3  None or any  
BM 5-9 % or 
PB 2-4 %,  
no Auer rods  
Any  
MDS-EB-2  0-3  1-3  None or any  
BM 10-19 % or 
PB 5-19 % or 





          
with 1 % blood 
blasts  1-3  1-3  None or any  
BM < 5 %,  
PB = 1 %*4, 






1  3  None or any  
BM < 5 %,  
PB < 1 %,  






0  1-3  < 15 %*5  
BM < 5 %,  
PB < 1 %,  
no Auer rods  
MDS-defining 
abnormality  
*1 Cytopenias defined as: haemoglobin, < 10 g/dl; platelet count, < 100 × 109/l; and absolute 
neutrophil count, < 1.8 × 109/l. Rarely, MDS may present with mild anaemia or thrombocytopenia 
above these levels. PB monocytes must be < 1 × 109/l. 
*2 If SF3B1 mutation is present. 
*3 Rod‐shaped inclusions formed by crystallisation of cytoplasmic azurophilic granules (25). 
*4 One percent PB blasts must be recorded on at least two separate occasions. 
*5 Cases with ≥ 15 % ring sideroblasts by definition have significant erythroid dysplasia, and are 
classified as MDS-RS-SLD. 
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MDS can also be classified according to their prognostic variables. To assess prognosis of primary 
untreated adult patients with MDS, the International Prognostic Scoring System (IPSS) was generated 
in 1997 (26). Based on cytogenetics, percentage of BM blasts and number of cytopenias (Table 3), 
the IPSS predicted disease outcome for survival and evolution to AML (Table 4). In 2012, the IPSS was 
refined and the Revised International Prognostic Scoring System (IPSS-R) was developed (27,28). 
The IPSS-R takes into account the risk of specific cytogenetic abnormalities present (Table 5), 
the number and degree of cytopenias, and proportion of blasts in BM. Score values for each 
prognostic variable are evaluated (Table 6) and the total score determines the risk category (Table 7). 
The IPSS-R stratifies patients into five risk categories: very low, low, intermediate, high, and very 
high. The two lowest categories are often referred to as ‘lower-risk’, whereas the two highest 
categories are referred to as ‘higher-risk’ MDS. The intermediate category is heterogeneous with 
some patient characteristics similar to lower-risk MDS and others to higher-risk MDS. Kaplan-Meier 
curves for clinical outcomes of patients within the five IPSS-R categories are shown in Figure 1 (27). 
To see how well prognostication or treatment work, overall survival (OS), progression-free survival 
(PFS), and overall response rate (ORR) are measured. 
 
Table 3. IPSS prognostic score values (26). 
Prognostic variable 
Score value 
0 0.5 1 1.5 2 
BM blasts (%) < 5 5-10 —  11-20 21-30 
Cytopenia*1 0-1 2-3    
Cytogenetics*2
 
Good Intermediate Poor   
— indicates not applicable 
*1 Number of lineages affected by cytopenia.  Cytopenias defined as: haemoglobin, < 10 g/dl; platelet 
count, < 100 × 109/l; and absolute neutrophil count, < 1.8 × 109/l. 
*2 Good: normal, -Y, -20q, -5q, Intermediate: all other, Poor: chromosome 7 aberration and/or ≥ 3 
chromosomal aberrations. 
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Table 4. IPSS risk categories, scores, and clinical outcomes (26). 
IPSS category IPSS score 
Overall survival*1 AML 25% evolution*2 
age at diagnosis (years) 
≤ 70 > 70 ≤ 70 > 70 
Low  0 9 3.9 > 9.4 (NR) > 5.8 (NR) 
Intermediate-1  0.5-1.0  4.4 2.4 5.5 2.2 
Intermediate-2  1.5-2  1.3 1.2 1.0 1.4 
High  > 2.5 0.4 0.4 0.2 0.4 
*1 medians, years 
*2 median time (years) to 25% AML evolution 
NR indicates not reached 
 
 




Very good -Y, del(11q) 
Good Normal, del(5q), del(12p), del(20q), double including del(5q) 
Intermediate del(7q), +8, +19, i(17q), any other single or double independent clones 
Poor -7, inv(3)/t(3q)/del(3q), double including -7/del(7q),  
complex: 3 abnormalities 
Very poor > 3 abnormalities 
 
  








0 0.5 1 1.5 2 3 4 
Cytogenetics  Very 





BM blasts (%) ≤ 2  —  >2 - <5  —  5-10  > 10  —  
Hemoglobin (g/dl) ≥ 10  —  8 - < 10  < 8  —  —  —  
Platelets (x109/l) ≥ 100  50 - < 100  < 50  —  —  —  —  
Neutrophils 
(x109/l) ≥ 0.8  < 0.8  —  —  —  —  —  
— indicates not applicable 
 








Very low  ≤ 1.5  8.8 NR 
Low  > 1.5-3  5.3 10.8 
Intermediate  > 3-4.5  3 3.2 
High  > 4.5-6  1.6 1.4 
Very high  > 6  0.8 0.7 
*1 medians, years 
*2 median time (years) to 25% AML evolution 
NR indicates not reached 
  















7.1.3 Somatic mutations 
Application of high throughput technologies such as next generation sequencing (NGS) has identified 
recurrent somatic mutations in MDS cells. Somatic mutations appear to have a great impact on MDS 
progression and prognosis, indicating their potential to contribute to better diagnosis and prognosis 
prediction. In 80 to 90 percent of MDS patients, recurring somatic mutations have been found 
in a number of genes involved in transcriptional regulation (TP53, RUNX1, GATA2, ETV6), signal 
transduction (JAK2, KRAS, CBL), DNA methylation (DNMT3A, TET2, IDH1/2), chromatin modification 
(EZH2, ASXL1), and RNA splicing (SF3B1, U2AF1, SRSF2) (29,30). Many specific mutations are strongly 
associated with the disease outcome in MDS, and the addition of mutation data improves 
the prognostic value of existing risk-stratification schemes in MDS (31). In particular, point mutations 
in TP53, EZH2, ETV6, RUNX1 and ASXL1 genes have been shown to be associated with specific clinical 
features and poor OS, independent of established risk factors (32). For example, TP53 mutations are 
associated with an aggressive course of MDS in general and appear to predict poorer response 
to lenalidomide treatment in patients with del(5q) (33). Evaluation for TP53 mutation status 
is recommended in patients with MDS with isolated del(5q) to identify an adverse prognostic 
subgroup (34,35) in this prognostically favourable MDS subtype. 
       OS                                                             AML evolution 
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Analysis of SF3B1 mutation is the first example of a genetic mutation included into the diagnostic 
criteria for MDS according to the 2016 WHO classification (24), as it is considered the important 
diagnostic method for diagnosis of MDS with ring sideroblasts (MDS-RS). Recurrent mutations 
in spliceosome SF3B1 gene are frequent and are associated with the presence of ring sideroblasts, 
which indicates more favourable prognosis of MDS-RS (36).  
In conclusion, patterns of somatic mutations are diverse in MDS. Even though majority of MDS 
patients carry at least one oncogenic mutation (29), there is a long list of mutations in more than 
50 genes with often unclear aetiology, complicating the use of somatic mutations as simple 
and universal markers of MDS prognosis. 
 
7.1.4 Treatment 
The heterogeneous nature of MDS demands a complex and personalized variety of therapeutic 
approaches. Among them, the only potentially curative option is haematopoietic stem cell 
transplantation (HSCT). Because MDS affect mostly the elderly, who are often frail with multiple 
comorbidities and cannot tolerate intensive therapeutic approaches, HSCT is accessible to only 
a limited number of fit patients. For majority of the patients with MDS, treatment strategies are 
nonintensive and risk-adapted, involving the definition of different aims of therapy according to the 
risk status of the patient (by the IPSS-R). These approaches are noncurative, but aimed at improving 
cytopenias and quality of life, and delaying disease progression. In all risk groups, supportive care 
with transfusions and antimicrobial drugs remains important. 
In the case of lower-risk MDS, therapy is mainly aimed at improving cytopenias, preventing 
complications, such as bleeding and severe infections, decreasing transfusion burden, and improving 
quality of life. In a substantial number of patients with mild and asymptomatic level of cytopenia, 
there is no need to go beyond supportive care, including blood transfusions and using antibiotics. 
For lower-risk patients with symptomatic anaemia, treatment with erythropoiesis-stimulating agents 
(ESAs) or immunomodulatory agent lenalidomide is appropriate. Studies suggest that treatment with 
ESAs leads to significant erythroid responses in 20 to 70 percent of unselected MDS patients and 
in approximately 40 percent of patients with LR-MDS. A median duration of treatment response 
is two years without an increasing risk of leukaemic progression. Lenalidomide was proven to be 
effective in the treatment of MDS patients with isolated del(5q) and lower-risk MDS patients, 
particularly in cases with 5q deletions. Some lower-risk patients may be candidates 
for immunosuppressive therapy, thrombopoiesis-stimulating agents, or DNA hypomethylating agents 
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(HMAs) azacitidine (AZA) and decitabine. All treatment decisions have to take into account 
a potential drug-induced deterioration of the patient’s clinical status (37–39).  
Among higher-risk patients, transplant candidates should undergo HSCT as soon as possible, 
with HMAs useful as a bridge to transplantation. For those patients who are not eligible for HSCT, 
HMAs therapy represents the only approved therapeutics and current standard of care (40). Further, 
HMAs and particularly AZA have been proven to be a valuable treatment also for patients who 
relapsed after HSCT (41). HMAs do not eradicate transformed cells, but can decrease clonal burden 
and may therefore improve haematopoiesis. They have been shown to improve OS, clinical 
outcomes, and quality of life of patients with advanced MDS (37,38). It was evaluated, however, that 
the ORR to AZA treatment ranges only between 40 to 50 percent (42,43) and the outcome of patients 
after treatment failure is very poor. 
Two HMAs approved for treatment of MDS, AZA and decitabine, are cytidine analogues which inhibit 
a group of enzymes called DNA methyltransferases (DNMTs) leading to demethylation of the cytosine 
residues in the promoter-associated CpG islands (40). The hypomethylation and subsequent 
turnaround in transcription of tumour suppressors and DNA repair genes is considered to be 
the main mechanism of HMAs action. In addition to epigenetic modulation, HMAs exhibit also 
immunomodulating effects and are able to incorporate into DNA and RNA molecules, but 
the contribution of these features to their clinical activity in MDS has not been established yet 
(40,44,45).  
 
7.1.5 Acute myeloid leukaemia 
AML is the most common acute leukaemia in adults. In majority of cases, it appears as a de novo 
malignancy in healthy individuals. However, it can also develop from an underlying haematologic 
disorder, or arise as a consequence of prior therapy. Regardless of its aetiology, the pathogenesis 
of AML involves the abnormal proliferation and differentiation of a clonal population of myeloid stem 
cells. The diagnosis of AML is established by the presence of 20 percent or more blasts of myeloid 
origin in BM or PB (46).  
AML is a highly heterogeneous disease and is classified into multiple categories by WHO according 
to cytogenetic and molecular abnormalities, degree of myeloid lineage differentiation, and dysplastic 
changes (24). Although AML patients can be stratified into favourable, intermediate, and adverse 
prognostic risk groups based on their cytogenetic profile, prognosis within these categories varies 
widely. AML associated with a prior haematologic disorder and therapy-related AML carry 
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a significantly poor prognosis. If AML is left untreated, patients usually die from infection or bleeding 
within months from diagnosis (46). 
About 30 percent of MDS patients develop AML (23), which is thus classified as AML 
with myelodysplasia-related changes (AML-MRC) (24). AML-MRC represents 25 to 34 percent of all 
AML diagnoses (47) and up to 48 percent of AML diagnoses in adults (48). It associates with adverse 
prognosis with lower remission rates and shorter OS compared to other AML categories. AML-MRC 
patients are treated with liposomal daunorubicin-cytarabine (CPX-351). Patients who are unable 
to tolerate intensive treatment with CPX-351 are commonly treated with AZA (47,48). 
 
7.2 Small noncoding RNAs 
At the end of the last millennium, the importance of noncoding RNAs was completely unknown. 
Up to that point, the scientific community had believed that noncoding RNAs are just transcriptional 
trash and had been focused exclusively on protein coding genes. Since the discovery of the first 
microRNA (miRNA), lin-4 from Caenorhabditis elegans, in 1993 (49,50), researchers have identified 
plenty of previously unknown noncoding RNA species and started to reveal their multiple functions 
affecting various biological processes and features of cells. 
 
7.2.1 Function and biogenesis of small noncoding RNAs 
Small noncoding RNAs (sncRNAs) refer to noncoding RNA species that are less than 200 nucleotides 
in length and share some molecular features and mechanisms of action in regulating of biological 
processes. SncRNAs are involved in the regulation of gene expression, RNA splicing, epigenetic 
processes, and chromatin structure remodelling. Thus, sncRNAs affect a variety of essential biological 
processes, such as cell proliferation, differentiation, apoptosis etc., and are critical for normal 
development. They are often expressed in a tissue-specific manner (51,52). A large amount 
of evidence indicates that sncRNA deregulation is associated with development of cancer and various 
diseases (53–56), including haematologic malignancies (57).  
So far, the most explored sncRNA species in humans are miRNAs. However, the current interest 
moves also towards non-miRNA sncRNA species such as piwi-interacting RNAs (piRNAs), small 
nuclear RNAs (snRNAs), small nucleolar RNAs (snoRNAs), small interfering RNAs (siRNAs), transfer 
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RNAs (tRNAs), and tRNA-derived small RNAs (tsRNAs) (Table 8). All these versatile sncRNA species are 
known to be key components of molecular interactions and gene regulation in eukaryotes (58). 
Although sncRNA families are different in their origin, they share specific steps in their biosynthetic 
pathways and regulatory mechanisms. They are produced by pathways containing specialized 
enzymes with nuclease activity able to excise small RNAs from specific RNA transcripts. 
The mechanism of sncRNA action is ensured by a group of effector proteins, that are commonly 
engaged within high molecular weight protein-RNA complexes, responsible for the stabilization, 
transport, and regulatory activity of sncRNAs.  
The following paragraphs provide a brief characterization of sncRNA species that are commonly 
detected within sncRNA profiling studies (i.e. miRNAs, piRNAs, snoRNAs, tRNAs, and tsRNAs) and are 
nowadays of special interest as potential disease biomarkers. 
 
Table 8. Basic characteristics of sncRNA species. 
sncRNA species Function Length 
miRNAs microRNAs 
RNAs that usually suppress the translation 
of target mRNA by binding to 3' UTR 






RNAs involved in retrotransposon 







RNAs that guide sequence-specific 
degradation of target mRNAs through 






RNAs located in the nucleus, involved 
in spliceosome formation (e.g., U1, U2, 
U5, U4, and U6) and RNA processing. 
Also commonly referred to as U-RNAs. 





RNAs located in the nucleolus, mostly 
involved in modification of other RNAs, 
such as ribosomal RNAs or spliceosomal 
RNAs. 
 60-250 nt 
tRNAs transfer 
RNAs 
RNAs that transfer amino acids to 





Recently identified RNA species 
with versatile roles in regulation 
of translation and ribosome biogenesis. 
14-50 nt 
 




miRNAs are short (∼ 22 nucleotides) endogenous single stranded noncoding RNA molecules and their 
sequences are highly conserved throughout various organisms. miRNAs play an essential role 
in the regulation of gene expression at the posttranscriptional levels. An individual miRNA is able 
to regulate the expression of more target mRNAs and each mRNA can be controled by several 
miRNAs. It is estimated that in humans, miRNAs regulate over 30 percent of protein coding genes 
(59). The ability of miRNAs to regulate thousands of mRNAs has raised an intensive interest in their 
role in physiological and pathological processes. It has been repeatedly proven that miRNAs play 
crucial roles in a wide variety of biological processes such as development, differentiation, 
proliferation, and apoptosis. Since they influence the expression of genes involved in fundamental 
signalling pathways, their deregulation often triggers various pathological processes and subsequent 
development of different diseases and cancers (60). In oncogenesis, some of deregulated miRNAs act 
as oncogenes or tumour suppressors (61). The majority of miRNAs are expressed in a tissue-specific 
manner. For example, miR-122 is preferentially expressed in liver (62), miR-124 in neurological 
tissues (63), miR-133 in muscles (64), and miR-208a in heart (65). Moreover, changes in the spectrum 
of tissue miRNAs correlate with various pathophysiological conditions (66). 
About half of all currently identified miRNAs are intragenic, mostly present in the intronic regions 
of protein coding genes, while the remaining miRNAs are intergenic, regulated by their own 
promoters. miRNAs can be localized in clusters and transcribed as one long transcript. 
In the dominant miRNA biogenesis pathway, the ‘canonical’ pathway (Figure 2), primary miRNA 
transcripts (pri-miRNAs) are cleaved into precursor miRNAs (pre-miRNA, ∼60 nt) by the ribonuclease 
III enzyme, Drosha. Pre-miRNAs are exported to the cytoplasm by Exportin 5, where they are cleaved 
into two mature (∼22 nt) miRNA molecules by the RNase III endonuclease Dicer generating a mature 
miRNA duplex. The directionality of the miRNA strand determines the name of the mature miRNA 
form. The 5p strand arises from the 5′ end of the pre-miRNA hairpin while the 3p strand originates 
from the 3′ end. Either of the strands derived from a mature miRNA duplex can be loaded 
into the Argonaute (AGO) family of proteins in an ATP-dependent manner to form the RNA-induced 
silencing complex (RISC). Although one of the strands is usually preferentially incorporated, 
the proportion of AGO-loaded 5p or 3p strand varies depending on the cell type or cellular 
environment, ranging from near equal proportions to predominantly one or the other. The sequence 
of the incorporated strand determines the targets that are recognized by RISC (67). Further, multiple 
non-canonical miRNA biogenesis pathways have been elucidated. These pathways use the proteins 
involved in the canonical pathway, mainly Drosha, Dicer, Exportin 5, and AGO2, but they use them 
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in different combinations. In general, the non-canonical miRNA biogenesis can be grouped 
into Drosha-independent (68) and Dicer-independent (69) pathways. 
Posttranscriptional regulation of gene expression is performed by binding of miRNAs to a specific 
sequence at the 3′ UTR of target mRNAs to trigger their degradation or repression depending 
on the miRNA/mRNA complementarity. Pairing with complete complementary target causes 
cleavage and subsequent degradation of the target mRNA, whereas imperfect complementarity 
leads to the RNA interference and translational repression. miRNAs bind also to 5′ UTR and coding 
regions, that have silencing effects on gene expression, and to promoter regions causing induction 
of transcription (67).  
 
Figure 2. The canonical pathway of miRNA biogenesis. Original figure from Wang et al. 2012 (70). 
The mature miRNA is highlighted in red. pri-miRNAs are processed by Drosha/DGCR8  
into pre-miRNAs. The pre-miRNA is transported from the nucleus to the cytoplasm by Exportin-5 
and Ran-GTP, where it is cut by a Dicer complex (Dicer/TRBP) into a miRNA/miRNA* duplex. One 
strand of the duplex is preferably incorporated into miRISC. DGCR8 – DiGeorge syndrome critical 
region 8, TRBP – TAR RNA-binding protein, miRISC – miRNA-induced silencing complex, ORF – open 
reading frame. 
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7.2.3 piwi-interacting RNAs 
piRNAs are short (24-31 nucleotides) single stranded RNA molecules longer than miRNAs. They bind 
to the piwi subfamily of Argonaut proteins forming piRNA silencing complex (piRISC), which is guided 
to the target nucleic acids in a sequence dependent manner. They arise from piRNA clusters located 
in genomic regions enriched in transposable and other repetitive elements, and are transcribed 
as long primary RNAs that are further processed to primary piRNAs through primary processing 
pathway. To enforce piRNA expression, primary piRNAs can subsequently enter an amplification 
system called the ‘ping-pong’ cycle, where they act as guides for the generation of secondary piRNAs 
(71). Unlike miRNAs, piRNAs have been described to function primarily through epigenetic 
modifications (71–73) rather than transcript targeting. While miRNAs are widely expressed in most 
mammalian cells and tissues, piRNAs are expressed mainly in the germline where they suppress 
transposable and repetitive elements to maintain genomic integrity. Nevertheless, it has been shown 
that piRNAs are expressed also in somatic tissues and tumour tissues in a tissue or cancer-specific 
manner (74,75). 
 
7.2.4 small nucleolar RNAs 
snoRNAs are noncoding RNAs that contribute to ribosome biogenesis and RNA splicing by modifying 
ribosomal RNA (rRNA) and spliceosomal RNAs, respectively. snoRNAs are longer than 
abovementioned sncRNA species and range from 60 to 300 nucleotides. They are components 
of small nucleolar ribonucleoproteins (snoRNPs), which are complexes controlling posttranscriptional 
modifications of ribosomal rRNA, snRNAs and probably other RNA species.  These modifications 
include 2′-O-methylation and pseudouridylation facilitating RNA folding and stability. snoRNAs are 
responsible for targeting the assembled snoRNPs to a specific target and directing the site-specific 
modifications of RNAs. Interestingly, instead of being transcribed from independent genes, most 
snoRNAs are processed from introns of precursor messenger RNAs (pre-mRNAs) (76,77). 
 
7.2.5 transfer RNAs and tRNA-derived small RNAs 
tRNAs help decode a messenger RNA (mRNA) sequence into a protein. Specific tRNAs transfer 
the appropriate amino acids to the ribosome for protein synthesis (78). Fragmentation of tRNAs 
generates a family of small RNAs collectively known as tRNA-derived small RNAs (tsRNAs). Although 
these tsRNAs were initially discarded as an artifact of RNA sequencing technology, there is 
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an increasing amount of evidence pointing to tsRNAs as biological entities with roles in translational 
regulation (79), gene silencing (80,81), and modulation of gene expression (82). They affect 
responses to various stress conditions (83–85), regulate mammalian development, haematopoietic 
stem cell fate and immune response (86), and play a role in pathological processes leading to cancer 
and other diseases development (87,88). Interestingly, some tsRNAs associate with Argonaute 
proteins and perform their functions as miRNAs (89). The biogenesis of tsRNAs is conserved 
and regulated process. They are generated from mature or precursor tRNAs by specific cleavage 
at different sites by specific RNases, including Dicer, RNase Z, and angiogenin (90,91). By different 
RNases, various types of tsRNAs are produced via different biogenesis pathways, which have not 
been fully uncovered yet.  
The nomenclature for tsRNAs is still inconsistent due to their recent identification. Based on cleavage 
sites of tRNAs and the length of generated tsRNAs, they can be divided into two main types:  
tRNA-derived fragments (tRFs), also called tRNA-derived RNA fragments (tdRs), and tRNA halves, also 
called stress-induced tRNA fragments (tiRNAs) as they are often generated in response to stress 
conditions. The first, tRFs, are about 14-30 nucleotides in length and are derived from the mature 
or pre-tRNAs. Up until now, four subtypes of tRFs have been identified and characterized by their 
location in the tRNA structure: 5-tRFs, 3-tRFs, 1-tRFs, and 2-tRFs. The second, tRNA halves, are 30-50 
nucleotides in length and produced by specific cleavage in the anticodon loop of mature tRNAs. Two 
subtypes of tRNA halves have been discovered, 5'-tRNA halves and 3'-tRNA halves. In summary, 
different types of tsRNA appear to accumulate during different biological processes via different 
biogenesis pathways (88). 
 
7.2.6 sncRNAs in normal haematopoiesis 
Stable haematopoiesis requires complex and careful regulation to maintain proper cellular 
proliferation and cell death modulation, cellular differentiation, and lineage commitment. During 
the last decade, the function of miRNAs in haematopoiesis was extensively studied, and many 
miRNAs playing a critical role in the development of both normal and malignant haematopoiesis 
were discovered. The role of other sncRNA species in haematopoiesis remain to be elucidated. 
In 2004, the first study exploring a role of miRNAs in the haematopoietic lineage differentiation 
showed that forced expression of miR-181 in haematopoietic stem/progenitor cells (HSPCs) markedly 
increases B cell differentiation, inhibits production of CD8+ T cells, and miR-142 decreases production 
of both CD4+ and CD8+ T cells, but does not affect B cells (92). Since then, many miRNAs specific 
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for the maintenance of the ‘stemness’ of HSCs and for the development of individual blood cell 
lineages have been determined (Figure 3). For example, it was shown that miR-125a and miR-29a are 
highly expressed in HSCs and modulates their self-renewal and numbers (93,94). Further,  
miR-29a is a key regulator of normal myeloid differentiation with tumour-suppressive function (95). 
miR-223 regulates granulocytic differentiation and function. This miRNA shows a highly lineage-
specific pattern of expression with its low levels in HSCs and common myeloid progenitors. 
The expression of miR-223 miRNA is steadily upregulated during differentiation to granulocytes and 
is repressed during differentiation to the alternative monocytic fate (96). MiR-451 is expressed 
predominantly in erythroid cells, its expression increasing during their maturation. In contrast,  
miR-221 and miR-222 are downregulated during erythroid differentiation. This downregulation 
enables the expression of their target gene encoding Kit receptor, whose activation triggers 
erythroblast expansion (97). Another miRNA, miR-150, is highly expressed in mature lymphocytes, 
whereas it is not active in HSCs (98). The target gene of miR-150 is transcription factor MYB that 
regulates lymphocyte development (99,100). miR-155, with its high levels in activated B-cells, T-cells, 
and monocytes, also participates in lymphoid differentiation (101). Further, the development  
of B-cells is positively regulated by miRNAs encoded in cluster miR-17-92. This cluster of miRNAs 
inhibits the expression of the apoptotic protein Bim and thus, plays a key role in pro-B cells to pre-B 
cells transition (102). Regarding specificity of miRNA profiles in haematopoietic cell lineages, 
expression analysis of 13 haematopoiesis related miRNAs in individual cell types from the PB 
of healthy individuals enables discrimination of individual blood cell lineages and determination 
of the cellular origin of in vitro cultured lines (103).  
Regarding recently acknowledged other sncRNA species, also snoRNAs were shown to be expressed 
in a lineage and development specific manner during haematopoiesis. Most significantly, snoRNAs 
located in DLK-DIO3 and SNURF/SNRPN imprinted loci are highly expressed in haematopoietic 
progenitors and downregulated during myeloid differentiation (104). 
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Figure 3. Schema of lineage differentiation in haematopoiesis and miRNAs involved in the process. 
Original  figure from Hrustincova et al. 2019 (105). CLP – common lymphoid progenitor, CMP – 
common myeloid progenitor, ETP – early thymic progenitor, GMP – granulocyte macrophage 
progenitor, HSC – haematopoietic stem cell, MEP – megakaryocyte erythroid progenitor, NK – natural 





7.2.7 sncRNAs in malignant haematopoiesis 
Many miRNAs, including the abovementioned, have been found to play a critical role 
in the pathogenesis and progression of haematopoietic disorders. For example, miR-125a knockout 
mice were shown to develop myeloproliferative disorders (106). In vitro, miR-125a-5p induces 
granulocytic differentiation in different human AML cell lines as well as in normal human primary 
HSPCs (107). Upregulation of miR-125a and miR-99b in macrophages lead to their polarization 
and secretion of inflammatory cytokines to kill tumour cells (108). Levels of miR-10a regulating 
myeloid differentiation are increased in AML (109) and atypical myeloproliferative neoplasms (110). 
Reduced levels of miR-29a and miR-142-3p were observed to be involved in AML development (95). 
Another study suggested that miR-29a initiates AML by converting myeloid progenitors into self-
renewing leukaemia stem cells (94). Further, miR-221 and miR-222 were found to be consistently 
overexpressed in AML (111). In AML cell lines, miR-223 was demonstrated to inhibit cell proliferation 
and enhance cell apoptosis, whereas it was observed to be suppressed in AML patients (112).  
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miR-126 inhibits cell apoptosis and increases viability of AML cells in vitro (113) and its higher level 
correlate with poorer prognosis in AML patients (114). Highly expressed miR-181a and miR-181b 
were identified in association with CEBPA gene mutations in cytogenetically normal AML patients 
(115). Finally, increased miR-150 expression was found to contribute to myelodysplastic 
haematopoiesis in MDS-del(5q) via its negative regulation of the transcription factor MYB (116). 
More details on sncRNAs in MDS are introduced in the chapter 7.3. 
The data on the role of other sncRNA species in haematopoietic diseases are still limited. A study 
focusing on snoRNA profiling in AML found a subset of snoRNAs that show consistent differential 
expression between AML and normal CD34+ cells, with the great majority of them being decreased 
in the AML samples (104). Another study found two tsRNAs downregulated in chronic lymphocytic 
leukaemia (CLL) patients. The authors performed further experiments to determine whether other 
tsRNAs are involved in CLL and revealed specific tsRNA signatures indicating that tsRNAs, like 
miRNAs, may have an oncogenic and/or tumour suppressor function in haematopoietic malignancies 
(117). In conclusion, it is evident that miRNAs and other sncRNA species are involved 
in haematopoiesis maintenance and their deregulation is associated with development 
of haematopoietic disorders. 
 
7.2.8 Circulating sncRNAs 
First extracellular sncRNAs were observed in blood in 2004 (118). In 2008, miRNAs were found 
in serum of patients suffering from diffuse large B-cell lymphoma (119). Since then, a great effort has 
been devoted to the research of this phenomenon. Nowadays, it is evident that miRNAs and other 
sncRNA species, originally found in tissues, are present not only in intracellular environment but also 
extracellularly in various body fluids such as blood plasma (120), serum (121), saliva (122), and urine 
(123). Moreover, their sncRNA profiles are significantly different. Examination of 12 human body 
fluids shows a distinct composition of the miRNA spectrum in various fluid types (124). 
The emergence of novel high-throughput technologies has allowed to analyse complete sncRNA 
profiles in different tissues as well as in biological fluids from healthy and diseased individuals.  
Extracellular sncRNAs released into blood circulation are referred to as ‘circulating’ sncRNAs. They 
are of special interest, because they originate from every tissue in the body, and their spectrum 
reflects overall condition of an organism. Thus, they are believed that they may serve as good blood-
based biomarkers of various diseases (125,126). Regarding this possibility, it was demonstrated that 
the quantity of some sncRNA species in blood would be sufficient to use them as biomarkers. Except 
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for most abundant miRNAs, also piRNAs and tRNAs are highly represented sncRNA species in body 
fluids (127,128). Most of the studies on circulating sncRNAs have been performed on total blood 
plasma or serum so far. With the extending knowledge that circulating RNAs are included 
in extracellular vesicles (EVs), which appear to have function in cell-to-cell communication, 
the studies move to exploring sncRNA contents also in plasma-derived EVs. Lots of studies were 
conducted in order to explore circulating sncRNA stability, functions, profiles, and their potential 
to serve as disease biomarkers. The knowledge is introduced in the following subsections. 
  
7.2.9 sncRNA stability, carriers, and sorting 
Several studies focused on sncRNA stability in human blood plasma and serum and found that they 
are remarkably stable under distinct conditions such as storage in room temperature, multiple 
freeze-thaw cycles (129), and long-term storage (130). It has been shown that circulating sncRNAs 
are protected from endogenous RNase activity (129), that degrades exogenously added RNA within 
seconds (131). This indicates that extracellular sncRNAs are unlikely to exist in an unprotected state. 
In the last decade, different sncRNA carriers and ways of sncRNA release from cells were revealed. 
Specifically, sncRNAs have been found to be included in EVs (132,133), incorporated in high density 
lipoproteins (HDL) (134), and associated with proteins such as AGO2 (135), the effector component 
of the RISC complex that directly binds miRNAs, or nucleophosmin 1 (NPM1) (136), which is involved 
in the biogenesis of ribosomes (Figure 4). 
Several types of EVs have been identified differing in their sizes and biogenesis. Exosomes  
(30-150 nm) (137) are formed as intraluminal vesicles within multivesicular bodies and are released 
into the extracellular space upon fusion of multivesicular bodies with the plasma membrane, 
whereas microvesicles (100-1000 nm) (138,139) are shed from the plasma membrane by outward 
blebbing (140). Another type of vesicles containing sncRNAs are apoptotic bodies (500-2000 nm) 
(141,142), which are released from the cell that undergoes apoptosis. 
Savelyeva et al. (143) found that a variety of blood plasma RNAs are comparable to the variety 
of cellular RNA species. Not only extensive set of miRNAs but also fragments of other cellular RNAs, 
such as rRNAs, tRNAs, mRNAs, lncRNAs, sncRNAs, and RNAs encoded by mitochondrial DNA (mtDNA) 
can be detected within EVs as well as in EV-depleted plasma (143). For example, a study profiling 
circulating RNAs of healthy individuals and cancer patients showed that in EVs, piRNAs are almost 
equally abundant as miRNAs (127).  
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Interestingly, EV-associated miRNAs appear to be more stable than those not associated with EVs 
(144). Another study suggested that exosomes are more protective of RNA degradation and provide 
more consistent source of miRNAs compared to intracellular and exosome-free plasma/serum 
miRNA contents (145).  
The sorting of sncRNAs into EVs and their secretion appear to be selective and controlled process. 
For example, HDL-associated miRNA profiles significantly differ from the exosome profiles both 
in miRNA spectrum and abundance (134). Another study revealed a significant difference in miRNA 
spectrum between microvesicles and their maternal cells, suggesting selective sorting of miRNAs 
into microvesicles (132). It was found that the sorting of miRNAs into exosomes is controlled 
by recognition of specific sequence motifs present in these miRNAs (146). Gámbaro et al. (147) 
investigated how sncRNA stability influences the sorting. They transfected cells with highly stable 
glycine 5' tRNA halves, which belong to the group of stress-induced tRNA fragments frequently 
detected in extracellular space and biofluids, and found that in contrast to unstable RNAs, these 
tRNA halves are present in EVs and in recipient cells in amounts proportional to the concentration 
of RNA used for transfection. Thus, the results suggested that even in the presence of selective 
sorting, the concentration of specific RNAs, which is given also by their stability, affects sorting 
of specific RNAs into EVs and their delivery in recipient cells (147).  
All these observations indicate that extracellular sncRNAs are not only mere leftovers of cellular 
metabolism as was believed not long ago, but they appear to play a critical role in intercellular 
communication that is mediated by EVs, and modulation of recipient cell features and functions. 
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Figure 4. Different ways of sncRNA release from cells to the extracellular environment. Edited figure 
from Hrustincova et al., 2015 (148). sncRNAs are included in EVs such as microvesicles and exosomes, 




7.2.10 EVs mediate cell-to-cell communication 
Nowadays, it is accepted that EVs released into extracellular environment enable a transfer of their 
molecular cargo to the recipient cells in the immediate vicinity or at distant locations via blood 
circulation and thus, EVs mediate cell-to-cell communication (149–151). In 2007, Valadi et al. (152) 
found that RNA cargo from exosomes can be delivered to another cell and in this recipient cell, it can 
be functional (152). Zhang et al. (153) reported that in human blood cells and cultured cells, miR-150 
is selectively packaged into microvesicles, actively secreted, and delivered into recipient cells, where 
it can participate in regulatory processes (153). It was observed that in AML, both primary cells 
and cell lines release exosomes that are received by neighboring cells. The exosomes are enriched 
for several RNAs, including miRNAs, relevant to AML pathogenesis. Moreover, these miRNAs regulate 
the biological functions of recipient cells (154). Another study indicated a direct effect of miR-150 
and miR-155 from AML exosomes on HSPCs. These miRNAs are enriched in AML exosomes 
and suppress translation of c-MYB, a transcription factor involved in HSPC differentiation 
and proliferation (155).  
Further findings of Huan et al. (156) suggested that AML exosomes regulate not only functions 
of HSPC directly, but also modulate BM compartmental signalling. Both in vivo and in vitro results 
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showed that AML cells increase exosome production under physiological oxygen conditions, which 
inhibits expression of HSC maintenance factors by stromal cells. Moreover, AML exosomes 
from extramedullary myeloid tumours appeare to traffic to BM niche and dysregulate niche signalling 
(156). Kumar et al. (157) showed that AML blast-derived exosomes transform the BM niche 
into a leukaemia growth-permissive microenvironment. These exosomes increase the number 
of mesenchymal stromal progenitors, block osteolineage development and bone formation in vivo, 
and accelerate AML growth. Conversely, disruption of exosome secretion in AML cells significantly 
delays AML development. Furthermore, AML-derived exosomes suppress production of HSC 
maintenance factors by stromal cells and thus, reduce their ability to support normal haematopoiesis 
(157). Regarding treatment, Chen et al. (158) indicated that AML-derived exosomes protect AML cells 
against chemotherapy via induction of IL-8 production in BM stromal cells. In addition, the study 
showed that IL-8 inhibition increases the sensitivity of AML cells to cell death (158). Another study 
showed that pre-therapy plasma of refractory or relapsed AML patients contains elevated levels 
of exosomes carrying immunosuppressive cargo that interfere with anti-leukaemia functions 
of activated immune cells used for adoptive cell therapy and reduce their therapeutic potential (159). 
In summary, exosomes mediate disruption of normal haematopoiesis in AML. Strategies to block 
their formation, secretion, and/or their modulatory effect on recipient cells might be utilized 
as a novel therapeutic approach in AML (160).  
The crosstalk between HPCs and their microenvironment was observed also in MDS. EVs derived 
from mesenchymal stromal cells of MDS patients were shown to carry different cargo compared 
to that of controls, including upregulated miR-10a and miR-15a. Further, they are able to incorporate 
into CD34+ cells, where their cargo modifies gene expression of MDM2 and p53, and induces cell 
viability and clonogenic capacity (161). Interestingly, miRNAs and piRNAs from BM mesenchymal 
stem cell EVs induce cell survival and inhibit cell differentiation of HSCs in umbilical cord blood (162). 
Because umbilical cord blood is an alternative source of HSCs for patients with haematologic 
diseases, who can be cured by allogeneic HSCT (163), this observation provides a new insight into 
the biology of umbilical cord blood transplantation. 
In conclusion, many studies have reported the significance of cell-to-cell communication through 
delivery of signal and regulatory molecules mediated by EVs. It has been shown that EVs carry a vast 
number of various molecules such as different RNA species (mRNAs, sncRNAs, and long noncoding 
RNAs), oncoproteins and oncopeptides, DNA fragments, and lipids, which induce phenotypic changes 
in recipient cells (164). There is comprehensive information on how the EVs derived 
from stem/progenitor cells inhibit or enhance immune response by affecting natural killer cells, 
dendritic cells, monocytes/macrophages, microglia, T cells, and B cells (165). Thus, EVs have crucial 
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roles in processes associated with cancer development (166–168), including leukaemia (169), where 
they modulate BM microenvironment, haematopoiesis, and the immune system to facilitate 
the malignancy. 
 
7.2.11 Circulating sncRNAs as biomarkers in haematologic malignancies 
The existing observations indicate that circulating sncRNAs play a critical role in (patho)physiological 
processes occurring in an organism. As they can be secreted from every cell and tissue in the body, 
they may very good reflect the actual condition of an organism and thus, may serve as valuable 
blood-based biomarkers of various diseases and cancers (125,126). Moreover, blood plasma and EVs 
are of special interest as a source of biomarkers because they can be obtained noninvasively, offering 
a novel feasible alternative to routine invasive BM biopsies, which can be demanding, especially 
for elderly patients with many comorbidities.  
The first evidence of the potential applicability of circulating miRNAs as noninvasive diagnostic 
markers was reported by Lawrie et al. in 2008 (119). They demonstrated that the levels of three 
tumour-associated miRNAs (miR-155, miR-210 and miR-21) were higher in the serum from patients 
with diffuse large B-cell lymphoma (DLBCL) than in controls. Moreover, they showed high level 
of miR-21 to be associated with relapse-free survival (119). Another study reported increased levels 
of miR‐21 in DLBCL cell lines and serum of DLBCL patients compared to controls (170), suggesting its 
potential utilization as biomarker for DLBCL diagnosis. On the contrary, Fang et al. (171) did not 
observe deregulated serum levels of miR-21 in DLBLC patients, but demonstrated increased levels 
of miR-15a, miR-16-1, miR-29c, and miR-155, and decreased level of miR-34a in DLBCL patients 
compared to controls (171).  
In AML, Fayyad-Kazan et al. (172) reported that miR‐150 and miR‐342 are significantly 
downregulated in plasma, and indicated that they may be potentially utilized as predictors of AML 
relapse (172). Plasma levels of miR-92a, miR-143 and miR-342 are decreased in AML patients 
and according to their specificity and sensitivity values, these miRNAs appear to be promising 
circulating biomarkers in clinical detection of AML (173). Further, Gado et al. (174) demonstrated 
decreased levels of miR-29a-3p and miR-92a-3p in both plasma and BM from AML patients along 
with increased expression of their target gene myeloid cell leukaemia sequence 1 (MCL1) in blood 
cells, which indicates diagnostic and therapeutic potential of these miRNAs (174).  
Low levels of circulating miR-92a were observed not only in AML (173–176), but also in multiple 
myeloma (177) and non-Hodgkin's lymphoma (178), suggesting that measurement of miR-92a level 
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in plasma may be useful for monitoring disease status or initiation of therapy in haematologic 
malignancies in general. miR-92a is a component of mir-17-92 cluster coding for a polycistronic 
transcript with pleiotropic functions. mir-17-92 is considered a polycistronic miRNA oncogene, whose 
overexpression is frequently observed in a variety of tumour types (179). Interestingly, Gu et al. (180) 
showed that miR-92a is downregulated in AML cell lines and its overexpression suppresses 
proliferation and induces apoptosis of AML cells through directly targeting 
methylenetetrahydrofolate dehydrogenase 2 (MTHFD2). Further, miR-92a overexpression in mice 
dramatically decreases tumour growth and MTHFD2 expression in vivo. The authors suggested that 
miR-92a may act as a tumour suppressor in AML and may be a promising therapeutic target for AML 
patients (180).  
Regarding circulating EVs and their sncRNA content, Hornick et al. (181) suggested that AML-derived 
exosomes and their miRNA content may be promising early biomarkers of AML as they can be 
detected in blood in advance of circulating blasts (181). Another study investigated the role 
of increased miR-125b level in circulating exosomes of intermediate risk AML patients. The results 
showed that high level of miR-125b is associated with higher-risk of relapse and overall death (182). 
 Relevance of circulating miRNAs to be blood-based disease biomarkers was further tested on other 
haematologic malignancies such as multiple myeloma (177,183–185), Hodgkin lymphoma (186),  
T-cell leukaemia (187), or chronic lymphocytic leukaemia (188–191). All of these studies suggested 
individual circulating miRNAs, such as miR-16-5p, miR-34a-5p, hsa-miR-29a-3p, hsa-miR-150-5p,  
hsa-miR-155-5p, miR-181a, miR-221, and miR-223-3p, to be useful diagnostic, prognostic, predictive, 
and survival biomarkers of specific diseases and also potential targets for therapy.  
 
7.2.12 Methodological aspects of sncRNA detection 
sncRNAs, especially those circulating in blood, appear to represent promising disease biomarkers. 
However, methods for sncRNA isolation, measurement, and quantification have specific limitations 
and critical technical hotspots, such as sample processing, inefficient isolation, haemolysis in blood 
samples, variable efficiency of reverse transcription and PCR, inconsistency in reference genes, 
and variability in genome-wide platforms used for sncRNA detection (148). Glinge et al. (192) 
highlighted the importance of proper and systematic sample collection, handling, and storage when 
measuring circulating sncRNAs. The study demonstrated that the results are affected by factors such 
as a type of collection tube (192). Variance in all procedures and methodological aspects lead 
to a discrepancy of the reported results. The inconsistent results obtained by various methods make 
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it difficult to define consensus disease biomarkers that may be implicated in clinical use. Thus, 
the methods are still being under development in order to improve their sensitivity, specificity, 
and reproducibility to avoid confounding variables influencing the results. More information 
on methodological aspects of sncRNA detection and quantification are discussed in our review (148). 
 
7.3 Small noncoding RNAs in myelodysplastic syndromes 
Nowadays, miRNAs and other sncRNA species are accepted as important regulators 
of haematopoiesis. Their abnormal function has serious implications for haematopoietic cell features 
and phenotypes. sncRNA deregulation has been found in haematopoietic disorders and naturally, 
it also contributes to the development and progression of MDS. Properties of sncRNAs such 
as stability and tissue specificity make these molecules highly promising diagnostic and prognostic 
biomarkers as well as interesting therapeutic targets. Particularly circulating sncRNAs are of special 
interest as they can be obtained noninvasively, unlike BM biopsies, which can be demanding for MDS 
patients. So far, miRNAs are the most explored sncRNA species in MDS. Although many studies have 
been conducted to investigate miRNA profile in MDS, there are not much overlapping results 
regarding deregulated individual miRNAs. This inconsistency may reflect large heterogeneity of MDS, 
but it may also be explained by nonuniformity in sample handling and processing procedures, 
and variability in platforms used for miRNA detection. Nevertheless, there is evidence that sncRNAs 
are aberrantly expressed in MDS, but their functions in MDS pathophysiology are mostly unknown 
and remain to be elucidated. Identifying the putative targets of specific sncRNAs is critical for better 
understanding of MDS. This section summarizes our knowledge on the contribution of sncRNAs 
to the pathogenesis of MDS and discusses their potential applicability in the assessment of disease 
diagnosis and prognosis. 
 
7.3.1 miRNAs deregulated in MDS and in particular MDS subtypes 
The initial studies in the field of miRNAs in MDS focused on characterization of miRNA profiles that 
are common in MDS or specific for individual MDS subtypes. In 2009, Pons et al. (193) measured 
expression levels of 25 haematopoiesis-related miRNAs in BM and PB of MDS patients. The study 
reported differentially expressed miRNAs between MDS and controls, such as an overexpression 
of miR-17-92 cluster in both BM and PB of MDS (193). Hussein et al. (194) demonstrated that 
the miRNA expression profile in BM cells can distinguish MDS patients with chromosomal alterations 
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from those with normal karyotypes (194). Another study examined global miRNA expression in BM 
mononuclear cells and observed high levels of miR-222 and miR-10a and low levels of miR-146a,  
miR-150, and let-7e in MDS (195). Dostalova Merkerova et al. (196) analysed miRNA expression 
at the genome-wide level in CD34+ BM cells and found significant differences in miRNA expression 
between early and advanced MDS subtypes. They further identified strong upregulation of miR-34a 
in early subtypes of MDS (196), corresponding with the results of another study, which reported 
substantial overexpression of miR-34a in MDS patients with del(5q) (197). 
MDS with isolated del(5q), formerly referred to as 5q-syndrome, is one of the best characterized 
MDS subtype. MDS with del(5q) is determined by haploinsufficiency of specific genes within 
commonly deleted region (CDR) localized in 5q31.3-5q33 locus, which is essential for its specific 
phenotype. In CDR, besides protein coding genes, 13 genes encoding miRNAs are located. In MDS 
with del(5q), decreased levels of miR-143-5p, miR-146a, and miR-378, mapped within CDR, were 
detected (196,197). Importantly, Starczynowski et al. (198) showed that the deletion of chromosome 
5q correlates with loss of miR-145 and miR-146a, which are abundant in HSPCs. TIRAP and TRAF6 
were identified as respective targets of these miRNAs. It is known that TIRAP lies upstream of TRAF6 
in an innate immune signalling pathway. Knockdown of miR-145 and miR-146a together or enforced 
expression of TRAF6 in mouse HSPCs result in thrombocytosis, mild neutropenia and megakaryocytic 
dysplasia. A subset of mice transplanted with TRAF6-expressing BM were observed to progress either 
to BM failure or to AML (198). Kumar et al. (199) showed that miR-145 loss in MDS with del(5q) 
affects megakaryocyte and erythroid differentiation. They reported that miR-145 functions through 
the repression of FLI1, a megakaryocyte and erythroid regulatory transcription factor. Inhibition 
of miR-145 increases the production of megakaryocytic cells relative to that of erythroid cells (199). 
Another study showed substantial overexpression of miR-34a in MDS patients with del(5q) (197). 
The expression of miR-34a is induced by p53 and it promotes apoptosis through inhibition of BCL2 
gene (200). Thus, high expression of miR-34a in MDS patients with del(5q) is likely to be related 
to an increased apoptosis of BM progenitors (201). 
 
7.3.2 miRNAs as MDS biomarkers 
Many studies have also focused on miRNA relevance and significance as potential MDS biomarkers. 
The earliest study in this area showed close association of miRNA profiles with IPSS score of MDS. 
A unique signature consisiting of ten miRNAs permitted discrimination between lower-risk 
and higher-risk disease. In addition, miR-181 family members were selectively overexpressed 
in higher-risk MDS and associated with shorter patient survival (195). Another study suggested that 
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increased expression of miR181a/b/d-5p may predict MDS to AML transformation (202). Pons et al. 
(193) explored the levels of haematopoiesis related miRNA in MDS and AML in order to seek a link 
between these miRNAs and MDS progression to AML. The results showed that the expression levels 
of miR-222 and miR-181a are higher in AML than in MDS in both BM and PB. Further, differential 
expression of miR-15a and miR-16 between lower-risk and higher-risk MDS groups was observed, 
suggesting that all these miRNAs may be implicated in the progression of MDS to AML (193). Lovat 
et al. (203) reported that double knockout of the two miR-15/16 loci in mouse leads 
to the development of AML and indicated that decreased levels of miR-15a/-15b/-16 in MDS patients 
predict the progression to AML (203). Finally, miR-22 upregulation in MDS appears to correlate 
with poor patient survival (204). 
 
7.3.3 miRNA functions in MDS 
Several studies focused on regulatory pathways and specific targets of individual miRNAs in MDS. 
For example, it was shown that overexpression of miR-125a in MDS CD34+ cells modulates NF-κB 
activation and enhances erythroid differentiation arrest (205). Upregulation of miR-34a in MDS 
reduces c-FOS expression leading to TNF-α overproduction, which is considered to cause ineffective 
haematopoiesis (206). miR-21 mediates ineffective haematopoiesis in MDS by activating TGF-β 
signalling via reducing expression of SMAD7 (207). Deregulation of miR-10a/b is controlled 
by TWIST1 and appeares to promote apoptosis via NF-κB and p53 (208). Another study reported 
induction of apoptosis in MDS via p53 activation by upregulated miR-661 (209). Similarly, miR‑143 
induces apoptosis in MDS through the Fas/FasL pathway (210). Downregulation of microRNA-144 
inhibits proliferation and promotes apoptosis of MDS cells through the activation of the AKAP12-
dependent ERK1/2 signalling pathway (211). Overexpression of miR-205-5p induces cell proliferation 
by suppressing PTEN (212). Finally, miR-22 targets TET2 tumour suppressor (204) leading to increased 
HSC self-renewal accompanied by defective differentiation (204). 
 
7.3.4 non-miRNA sncRNA species in MDS 
With the development of high-throughput sequencing technology, the first studies observing other 
sncRNA species have emerged, investigating their expression and potential as disease biomarkers. 
Beck et al. (213) determined sncRNA and coding gene expression in primary BM cells of MDS patients 
and performed integrative analysis of the data. The analysis showed that in early MDS, the sncRNA 
profile is enriched in piRNAs, potentially protecting DNA from the accumulation of mutations. 
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In advanced MDS, tRNAs are enriched, possibly contributing to the reduction of apoptosis, which is 
characteristic for advanced stage of the disease (213). Guo et al. (202,214) demonstrated the utility 
of tsRNAs as predictive biomarkers for both, response to therapy with HMAs (214) and MDS 
progression to AML (202). In the first study (214), the authors reported that tsRNAs are one 
of the most common sncRNA species and some of them are associated with response 
to the treatment (214). In the second study (202), they identified miRNAs (miR-181a/b/d-5p,  
miR-199b-5p, and miR-486-5p) and tsRNAs that predict progression of MDS to AML independently 
of increased blast percentage, emphasizing their value as true predictive markers of future 
transformation instead of just documentation of the disease progression. In addition, the results 
indicated that the production of tsRNAs is specific (202). Interestingly, it was shown that 
pseudouridylation of tsRNAs mediated by pseudouridine synthase 7 (PUS7) directs them to inhibit 
translation and this phenomenon critically governs HSC commitment, HSPCs differentiation 
and haematopoietic lineage specification. Moreover, deregulation of this regulatory pathway 
appears to be common for MDS with the deletion of chromosome 7, where PUS7 gene is located 
(215). 
 
7.3.5 Circulating sncRNAs in MDS 
To date, only a few studies have investigated circulating sncRNAs in MDS. First studies focused 
on plasma/serum levels of specific miRNAs. Guo et al. (216) found that the levels of let-7a and  
miR-16 are decreased in MDS plasma compared to controls, and associated with patient PFS and OS 
(216). Kim et al. (217) investigated the level of miR-21 in serum of MDS patients treated with HMAs. 
The results showed that serum level of miR-21 differentiate responders from nonresponders and is 
associated with ORR and PFS of MDS patients treated with HMAs (217). Thus, initial studies showed 
that in MDS, specific circulating miRNAs may serve as predictive biomarkers of survival and response 
to HMAs therapy.  
With developing high-throughput technologies, analysis of up to thousands of predefined miRNAs 
became available.  Zuo et al. (218) were the first who investigated the global profile of circulating 
miRNAs in MDS plasma. They analysed 800 miRNAs and identified a 7-miRNA signature (let-7a,  
miR-16, miR-25, miR-144, miR-451, miR-651, and miR-655) as an independent predictor of survival 
in MDS patients with normal karyotypes (218). With unravelling the role of EVs as mediators 
of intercellular communication, research has focused on investigation of the EV cargo. Giudice  
et al. (219) explored the possible diagnostic and prognostic potential of plasma exosomal  
miRNAs and found 21 miRNAs that appear to be strongly associated with MDS.  
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Further, with the development of next generation sequencing, other sncRNA species became 
detectable. Enjeti et al. (220) sequenced sncRNA content in microvesicles of MDS patients and 
revealed that the sncRNA cargo of MDS microvesicles is approximately twice as high as that 
of microvesicles of controls. Furthermore, miRNA content and characteristics of microvesicle 
population of MDS patients were significantly different than those of controls (220).  
To conclude, circulating sncRNAs have a great potential to become a noninvasive biomarkers 
of the disease, which would highly contribute to improving MDS diagnostics, prognosis assessment, 
treatment, and patient comfort. Thus, there is a great effort to uncover the real value and features 
of these molecules, and find a way to utilize them in clinical practice.  
 




We aimed to analyse sncRNA expression using high-throughput technologies to identify sncRNA 
profiles associated with MDS development, progression, and treatment, and to search for novel 
prognostic and predictive biomarkers of the disease and response to AZA therapy, respectively. 
 
8.1.1 Specific aims 
1. Characterization of specific sncRNA profiles associated with MDS subtypes and risk groups 
and determination of sncRNAs with different levels between 
i. MDS patients and healthy individuals 
ii. patients with different MDS subtypes 
iii. patients with lower-risk and higher-risk MDS  
iv. MDS and AML-MRC patients 
v. MDS patients responsive and nonresponsive to AZA therapy. 
 
2. Characterization of sncRNA profiles in different materials and their comparison between 
i. BM cells and total plasma (i.e. intracellular versus extracellular sncRNAs) 
ii. total plasma and EVs (different extracellular materials) 
in order to define source-related specificities in sncRNA levels, their association with the patient 
outcome and to find which of the two extracellular materials would be suitable as possible source 
of circulating sncRNA biomarkers. 
 
3. Determination of sncRNAs that may serve as auxiliary MDS biomarkers for prediction of patient 
outcome and AZA therapy responsiveness. Achieving this goal included  
i. correlation of specific sncRNA signatures with clinical data, particularly with regard to patient 
follow-up (i.e. patient survival, progression of the disease, and response to AZA therapy) 
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ii. assessing of predictive value of selected sncRNAs at the level of both individual molecules 
and multiple molecule signature 
iii. validation of the high-throughput data of particular sncRNAs on an independent or extended 
sample cohorts using quantitative methods to prove the accuracy of the results and to study 
association of these sncRNAs with clinical characteristics more precisely. 
 
4. Identification of biological pathways potentially affected by the deregulated sncRNAs that may 
underlie the pathophysiology of MDS. 
 




Most of the methods described below were applied in all the three publications that underlie this 
thesis. When applied under specific conditions in the particular publication, it is indicated as P1, P2, 
and P3. For references see the Preface.  
 
9.1.1 Patient samples 
The PB and BM aspirates were collected from patients with MDS and AML-MRC with no known 
history of previous malignancy, chemotherapy, or radiation therapy. The samples were obtained 
from the Clinical Departments of the Institute of Hematology and Blood Transfusion and the General 
University Hospital in Prague. None of the patients had received drug therapy for their disease 
or HSCT prior to blood collection, except for patients involved in the study of AZA treatment 
response. The patient’s diagnoses were assessed based on the standard 2008 or 2016 WHO 
classification criteria (23,24), and all the patients were classified according to the IPSS (26) or IPSS-R 
categories (27).  
PB samples and BM aspirates from age-matched healthy donors with no adverse medical history 
were used as controls. Written informed consents were obtained from all tested subjects 
in accordance with the ethical standards of the Declaration of Helsinki and its later amendments. 
The study was approved by the Institutional Scientific Board and the Local Ethics Committee. 
Regarding AZA therapy, AZA was administered at 75 mg/m2/day for seven consecutive days every 
28 days. The haematologic evaluation of the response to the treatment was performed after the 
fourth cycle according to the International Working Group (IWG) criteria for MDS (221) and AML 
(222). Patients who achieved complete remission (CR), partial remission (PR), marrow complete 
remission (mCR), or haematologic improvement (HI) were considered responders, whereas patients 
with stable disease (SD) or progressive disease (PD) were considered nonresponders.  
The detailed characteristics of individual sample cohorts are included in the appropriate Results 
sections of P1, P2, and P3. 
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9.1.2 Cell separation 
Mononuclear cells (MNCs) were separated from the BM aspirates by Ficoll-Paque density 
centrifugation (GE Healthcare, Munich, Germany). CD34+ cells were isolated from MNCs using 
the Direct CD34 Progenitor Cell Isolation MACS Kit (Miltenyi Biotec, Bergisch Gladbach, Germany). 
Both procedures were performed according to the manufacturer’s instructions.  
 
9.1.3 Separation of blood plasma 
PB was collected in EDTA tubes, and blood plasma was separated from the PB by centrifugation 
at 460 g for 10 min. The absence of haemolysis in plasma samples was confirmed 
spectrophotometrically by measuring oxyhaemoglobin absorbance at 414 nm and by qPCR evaluating 
the ratio of miR-451 to miR-23a (delta Cq (miR-23a - miR-451a)) (223,224) using StepOnePlus  
Real-Time PCR System (Thermo Fisher Scientific, Waltham, MA, USA). Only samples 
with the oxyhaemoglobin absorbance less than 0.2 and delta Cq (miR-23a - miR-451a) less than 
5 were included. Plasma samples were further centrifuged at 12,000 g at 4°C for 15 min to remove 
cell debris and after gradual freezing stored at -80°C. 
 
9.1.4 Separation of extracellular vesicles 
EVs were extracted from plasma using the ExoQuick Plasma Prep and Exosome precipitation kit 
(System Biosciences, Palo Alto, CA, USA). Briefly, plasma samples were pretreated with thrombin  
(5 U/mL) and centrifuged to dispose of fibrin and cell debris. Then, EVs were precipitated from 250 
µL of pretreated plasma using ExoQuick according to the manufacturer’s protocol.  
 
9.1.5 Transmission electron microscopy 
Transmission electron microscopy (TEM) was used to confirm the presence and size of EVs. It was 
done in cooperation with Romana Hadravová from the Institute of Organic Chemistry 
and Biochemistry of Academy of Sciences of the Czech Republic. EVs were visualized by negative 
staining. Briefly, Parlodion-carbon-coated grids were floated on the top of a 5 µl drop of the sample 
for 5 min. Then, the grids were transferred on the top of a drop of 2% phosphotungstic acid (pH 7.4), 
stained for 2×1 min and dried. Photomicrographs were taken with JEOL JEM-1011 electron 
microscope (JEOL, Peabody, MA, USA) operated at 80 kV.  
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9.1.6 Nanoparticle tracking analysis  
Nanoparticle tracking analysis (NTA) was used to define size and quantity of EVs. It was done 
in cooperation with Jaroslav Hanuš from the University of Chemistry and Technology in Prague. NTA 
was performed using Malvern NanoSight NS300 instrument (Malvern Panalytical, Malvern, UK). 
Briefly, purified EVs were diluted 5 x 103 in PBS and tracked using NTA analysis software. Each sample 
was analysed 3 times, and the counts were merged.  
 
9.1.7 Western blotting 
Western blotting was performed to confirm the presence of exosomes in isolated EV fractions. It was 
done in cooperation with Tereza Hrdinová and Matyáš Krijt from the Department of Proteomics, 
Institute of Hematology and Blood Transfusion (IHBT) in Prague. Briefly, EVs and K562 total cell lysate 
(used as a positive or a negative control) were lysed in 200 µl of NaCl-HEPES + 0,15% Triton  
(Sigma-Aldrich, St. Louis, MO, USA) and incubated on ice for 20 min. Total protein concentration was 
quantified by the Bradford protein assay (Bio-Rad, Hercules, CA, USA) and 30 µg of proteins were 
separated on 4 - 15% Mini-PROTEAN TGXTM gels (Bio-Rad) and transferred to polyvinylidene 
difluoride (PVDF) membrane. The membrane was blocked with SuperBlock blocking buffer (Thermo 
Fisher Scientific) and immunostained. The following primary antibodies were used: mouse anti-CD81 
antibody (1:1,000) (B11, sc-166029, Santa Cruz Biotechnology, Dallas, Texas, USA), rabbit anti-CD9 
antibody (1:1,000) (EXOAB Kit 1, System Biosciences, Palo Alto, CA, USA) and rabbit anti-calnexin 
(C5C9) antibody (1:1,000) (2679, Cell Signaling Technology, Danvers, MA, USA). Secondary 
horseradish peroxidase-conjugated anti-rabbit (7074P2, Cell Signaling Technology) or anti-mouse 
(7076P2, Cell Signaling Technology) antibodies were used. For imaging, Westar Supernova ECL 
substrate was used (Cyanagen, Bologna, Italy). 
 
9.1.8 RNA extraction 
Different methods of RNA extraction were used to meet the requirements of downstream 
applications on RNA purity and input. 
In P1 and P3, RNA from total plasma and CD34+ cells, respectively, were isolated using a phenol-
chloroform extraction (225). In P1, Trizol LS reagent (Invitrogen, Basel, Switzerland) was used 
and the procedure was modified according to Filková et al. (226). 
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In P2, RNA from total plasma and EVs was extracted using the miRNeasy Serum/Plasma Kit (QIAGEN, 
Hilden, Germany) according to the manufacturer’s protocol.  
RNA concentration was quantified with NanoDrop spectrophotometer (Thermo Fisher Scientific) 
and Qubit 2.0 fluorometer using Qubit microRNA Assay Kit, Qubit RNA HS Assay Kit, and Qubit RNA 
BR Assay Kit (Thermo Fisher Scientific). Integrity of RNA from CD34+ cells was evaluated with Agilent 
Bioanalyzer 2100 (Agilent Technologies, Santa Clara, CA, USA). 
 
9.1.9 miRNA profiling with microarrays and data analysis 
miRNA profiles were determined using Agilent Human miRNA Microarrays (Sure Print G3 
Unrestricted miRNA 8x60K, Release 19.0, Agilent Technologies). The input amounts of total RNA 
from plasma (P1) and from cells (P3) were 350 ng and 200 ng per sample, respectively. The samples 
were processed according to the manufacturer’s protocol. Scanning was performed on an Agilent 
Microarray Scanner.  
Data extraction and quality control were performed by Agilent Feature Extraction Software 
(v10.7.3.1). The data were normalized and processed in R statistical software (www.r-project.org) 
with the AgiMicroRNA (227) and its web interface MagiCMicroRna (228) packages in cooperation 
with Viktor Stránecký from the Institute of Inherited Metabolic Disorders in Prague. 
Differential gene expression analyses were performed in R using the gtools package (|FC| and its 
modifications). Subsequent data analyses were performed using MeV v4.8.1 software (229). Analysis 
of variance (ANOVA) was performed to identify differentially expressed miRNAs between different 
groups of samples. Welch’s approximate t-test was applied to determine differentially expressed 
miRNAs between two sample groups. Multiple testing correction was performed using  
the Holm-Bonferroni method. Hierarchical clustering of the miRNA expression data was done 
by using average linkage and Euclidean distance. 
 
9.1.10 Small RNA-seq and data analysis 
All sequencing libraries were constructed from 5 µl of RNA (RNA was isolated from plasma (200 µl) 
and EVs (precipitated from 250 µl of plasma) and was eluted to 30 µl Rnase-free water). The libraries 
were prepared, amplified, and purified using a QIAseq miRNA Library Kit (QIAGEN) following 
the manufacturer’s protocol. The concentration and size of the purified libraries were measured 
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with Qubit 2.0 fluorometer using Qubit dsDNA HS Assay Kit and Agilent 4200 TapeStation using 
D1000 Screen Tape Assay (Agilent Technologies), respectively. Libraries were adjusted to 4 nM, 
pooled together, and sequenced on HiSeq 2500 sequencer (Illumina, San Diego, CA, USA) as single 
reads for 83 cycles. 
After quality control of raw data using the FastQC tool (230), the sequences were processed using 
the QIAseq miRNA Primary Quantification pipeline (QIAGEN) available via The GeneGlobe Data 
Analysis Center. Briefly, 3’ adapter and low-quality bases were trimmed using Cutadapt (231), 
and the insert sequences and unique molecular indices (barcodes) were identified. The reads shorter 
than 16 nucleotides were discarded from the analysis. Sequences were then aligned using 
a sequential alignment strategy to map to different databases (perfect match to miRBase mature, 
miRbase hairpin, noncoding RNA, mRNA and other RNA, and finally the second mapping to miRBase 
mature, in which up to two mismatches were tolerated) using Bowtie (232). At each step, only 
unmapped sequences were passed to the next step. miRBase v21 was used for annotation 
of miRNAs, and piRNABank was used for piRNAs. All remaining unaligned sequences were mapped 
to the GRCh38 genome.  
De novo miRNAs were predicted using the miRdeep2 tool. The origin of nonhuman RNAs was 
identified by metagenome analyzer MEGAN (233). Due to an excessive amount of data, 
the nonhuman RNAs were analysed only on some of the samples (11 patients and 3 controls) using 
50,000 randomly selected reads (the number was assessed as sufficient for the analysis based 
on a taxonomy rarefaction plot). 
Annotated read counts were subsequently processed in R statistical environment. Data normalization 
and subsequent statistical analyses were performed using the edgeR package (234). Binary 
logarithms of fold changes (logFC) and q values (False Discovery Rate (FDR) adjusted p value) were 
generated as an output of edgeR package for differential expression analysis of the data. Analyses 
were considered statistically significant if q < 0.05. Hierarchical cluster analysis was performed using 
the pvclust package (235) with average correlation. RNA-seq analysis was done in cooperation 
with David Kundrát, Department of Genomics, IHBT, Prague. 
 
9.1.11 Reverse transcription quantitative PCR 
Reverse transcription quantitative PCR (RT-qPCR) was performed for relative quantification 
of individual sncRNA levels. Reverse transcription reactions were prepared with TaqMan MicroRNA 
cDNA synthesis kit (Thermo Fisher Scientific) following the manufacturer´s instructions.  
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A no template control and a negative control for each RT reaction were included in every assay.  
qPCR reactions were prepared using TaqMan MicroRNA assays and TaqMan Universal Master Mix II, 
no UNG (both Thermo Fisher Scientific) and performed on StepOnePlus real-time PCR system 
(Applied Biosystems, Foster City, CA, USA). The assays were designed and verified by the producing 
company (Thermo Fisher Scientific) and are commercially available. The individual assays  
are specified in the Results. The data were normalized to RNU48 and processed by the 2-ΔΔCT method 
(236).  
 
9.1.12 Droplet digital PCR 
Droplet digital PCR (ddPCR) was performed to quantify absolute levels of individual sncRNAs.  
RT reactions were prepared with TaqMan MicroRNA Reverse Transcription Kit (Thermo Fisher 
Scientific) following the manufacturer´s instructions. A no template control and a negative control for 
each RT reaction were included in every assay. PCR reactions were prepared using ddPCR Supermix 
for Probes (Bio-Rad) and TaqMan MicroRNA assays (Thermo Fisher Scientific). The assays were 
designed and verified by the producing company (Thermo Fisher Scientific) and are commercially 
availabe. The individual assays are specified in the Results. Droplets were prepared using QX200 
Automated Droplet Generator. After PCR, signals were detected on QX200 Droplet Reader 
with QuantaSoft software (all from Bio-Rad).  
 
9.1.13 Mutational screening and data analysis 
Mutational screening was performed as a part of routine clinical assessment using the TruSight 
Myeloid Sequencing Panel Kit (Illumina) containing 568 amplicons of 54 genes associated with 
myeloid malignancies. It was done in cooperation with Jitka Veselá, Monika Hrubá, and Katarina 
Szikszai, Department of Genomics, IHBT, Prague. The amplicon library was constructed according 
to the manufacturer’s recommendations. The libraries were 2x150 bp paired-end sequenced 
on a MiSeq instrument (Illumina), and the data were analysed using NextGENe software 
(SoftGenetics, State College, PA, USA). The clinical significance of each variant was verified in several 
genomic databases (UCSC, COSMIC, ExAC, and PubMed). The arbitrary cut off was set at three 
percent of variant allele frequency (VAF). 
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9.1.14 Statistical analysis 
Statistical analyses were performed using GraphPad Prism (GraphPad Software, La Jolla, CA, USA). 
Unpaired or paired tests (when appropriate) were used to compare continuous variables between 
different groups of samples. Based on data normality distribution (according to Shapiro-Wilk test), 
appropriate parametric or nonparametric variants of testing were utilized. The chi-squared test was 
applied for the comparison of categorical clinical variables. Pearson correlation analysis was 
performed to identify possible dependence between continuous variables. The sensitivity 
and specificity of the optimum cut-off points were defined as the values that maximized the area 
under the receiver operating characteristic (ROC) curve (AUC). The progression-free survival (PFS) 
and overall survival (OS) curves were generated by the Kaplan-Meier method, and the differences 
between groups were assessed by the log-rank test. Multivariate analysis was performed using 
the Cox proportional regression model. Results were considered statistically significant if p < 0.05. 
All statistical analyses were done in cooperation with Pavla Pecherková, Department of Biostatistics 
and Bioinformatics, IHBT, Prague. Analyses with more details are specified in the Results. 
 
9.1.15 miRNA pathway analysis 
Pathway analysis was done to identify signalling pathways that may be affected by specific miRNAs. 
The analysis was based on the data on significant differences in miRNA levels using DIANA-miRPath 
v3.0 (237). Within the analysis, target prediction of miRNAs was computed using the DIANAmicro 
T-CDS, and the most significantly affected KEGG pathways were identified. 
 




The Results section comprises three subsections presenting the results from the three publications 
(Publication 1, Publication 2, and Publication 3 as indicated in the Preface). 
 
10.1 Publication 1 
Dostalova Merkerova et al., Microarray profiling defines circulating microRNAs associated 
with myelodysplastic syndromes, Neoplasma, 2017 
 
In this study, we investigated levels of 2,006 predefined miRNAs in total blood plasma from MDS 
patients using microarrays. We found that specific miRNAs are significantly deregulated between 
lower-risk and higher-risk MDS patients and associate with progression and survival, suggesting that 
specific circulating miRNAs may serve as biomarkers of MDS patient outcome.  
 
10.1.1 Patient cohort 
The study was conducted on a cohort of 60 individuals, who included 40 MDS patients and 20 healthy 
individuals as controls. Based on the WHO classification criteria from 2008 (23), the diagnoses 
of MDS patients were as follows: 2 RCUD, 3 RARS, 17 RCMD, 4 RAEB-1, and 14 RAEB-2. The detailed 
clinical characteristics of all patients are summarized in Table 9. 
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Table 9. Characteristics of the patients. The data are presented as the mean and range for all 
continuous variables. 
Number of patients 40 
Sex (male/female) 30/10 
Age (years) 66 (40-85) 
Diagnosis (RCUD/RARS/RCMD/RAEB-1/RAEB-2) 2/3/17/4/14 
IPSS category (low/intermediate-1/intermediate-2/high) 4/20/10/6 
IPSS karyotype (good/intermediate/poor) 25/9/6 
Cytogenetics  
normal karyotype 23 
isolated del(20q)   2 
isolated +8  2 
complex 6 
other  7 
BM blasts (%) 6.1 (0.0-19.6) 
Haemoglobin (g/l) 100 (51-138) 
Neutrophils (x109/l)  1.9 (0.2-8.6) 
Platelets (x109/l)   123 (13-528) 
Follow-up               number of patients 
                                 mean follow-up (months) 
38 
22.7 (2.3-78.5) 
i. stable disease    number of patients  
                                 mean follow-up (months) 
16 
27.7 (3.2-78.5) 
ii. progression       number of patients 
                                 mean time from diagnosis (months) 
22 
14.3 (2.3-58.0) 
iii. HSCT                   number of patients 
                                 mean time from diagnosis (months) 
7 
6.7 (2.3-13.4) 
iv. death                 number of patients 





10.1.2 miRNA profiling in MDS plasma 
miRNA profiling was performed using microarrays. For this high-throughput analysis, only 21 samples 
(14 patients and 7 controls) were selected, due to limited budget. The complete raw and normalized 
data have been deposited in the NCBI Gene Expression Omnibus (GEO) database and are accessible 
through GEO Series accession number GSE76775.  
Among 2,006 miRNAs present on the array, expression of 207 and 201 miRNAs was detectable 
in MDS and control samples, respectively. Only the miRNAs that were detected in more than 
4 samples were included for further analysis. The Welch t-test was applied to determine miRNAs 
differentially expressed between two groups of samples: (i) patients and controls and (ii) lower-risk 
and higher-risk patients. Comparative analysis identified 48 miRNAs showing significantly (p < 0.01) 
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altered levels in plasma of MDS patients (irrespective of their clinical parameters) compared to those 
in plasma of controls (Figure 5). Among these miRNAs, 19 were downregulated (e.g. miR-451a,  
miR-92a-3p, miR-320a/b/d/e, and miR-142-3p/5p), and 29 were upregulated (e.g. miR-150-5p, 
miR188-5p, and miR-371b-5p) in patients. Between lower-risk (N = 8) and higher-risk (N = 6) MDS 
patients, 17 miRNAs were identified as deregulated. For example, miR-16-5p, miR-17-5p,  
miR-27a-3p/b-3p, miR-223-3p were downregulated and miR-188-5p, miR-623 were upregulated 
in higher-risk patients (Figure 6). 
 
10.1.3 Quantification of individual miRNA levels by ddPCR 
Levels of specific miRNAs were quantified by ddPCR in the cohort of all samples. Based 
on the microarray results, we selected six haematopoiesis and/or oncology related miRNAs  
(miR-16-5p, miR-27a-3p, miR-150-5p, miR-199a-5p, miR-223-3p, and miR-451a) that showed 
deregulated levels in MDS plasma. In concordance with the microarray data, plasma miR-150-5p was 
increased and miR-16-5p, miR-27a-3p, miR-199a-5p, and miR-451a were decreased in MDS patients 
compared to controls. Comparison of miRNA levels between higher-risk and lower-risk patients 
revealed significantly (p < 0.05) lower levels of miR-27a-3p, miR-199a-5p, and miR-223-3p  
in higher-risk patients (Figure 7).  
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Figure 5. miRNAs deregulated in MDS plasma compared to control plasma. The heatmap shows 
miRNAs with deregulated levels (p < 0.01) in all MDS patients compared to controls. Color gradient 
intensity scale indicates binary logarithm of fold change (logFC) of signal intensities compared with 
the mean signal intensity of controls. Red indicates increased level of miRNA, green indicates 
decreased level of miRNA. Each column represents a patient, and each row represents a miRNA.  
LR – lower-risk MDS patient, HR – higher-risk MDS patient 
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Figure 6. miRNAs altered between lower-risk and higher-risk MDS in plasma. The heatmap shows 
miRNAs with deregulated levels (p < 0.01) between lower-risk and higher-risk MDS patients. Color 
gradient intensity scale indicates logFC of signal intensities compared with the mean signal intensity 
of controls. Red indicates increased level of miRNA, green indicates decreased level of miRNA. Each 
column represents a patient, and each row represents a miRNA. LR – lower-risk MDS patient,  




Figure 7. Levels of specific miRNAs in plasma. Absolute amounts of miR-16-5p, miR-27a-3p,  
miR-150-5p, miR-199a-5p, miR-223-3p, and miR-451a were quantified with ddPCR. CTR – control,  
LR – lower-risk MDS, HR – higher-risk MDS, * p < 0.05, ** p < 0.01, *** p < 0.001 
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10.1.4 Correlation of circulating miRNA levels with clinical variables 
A series of univariate analyses was performed for various clinical variables and for each of the six 
selected miRNAs to evaluate whether their plasma levels are potential predictors of patient 
outcomes. The mean patient follow-up was 22.7 months, and within the monitoring period,  
22 patients progressed, and 11 patients died. The univariate analysis indicated significantly different 
PFS (p < 0.05) associated with the following parameters: IPSS karyotype, IPSS score, amount 
of cytopenias, WHO-based diagnosis, and the levels of five miRNAs (miR-27a-3p, miR-150-5p,  
miR-199a-5p, miR-223-3p, and miR-451a). The univariate analysis for OS showed distinct 
stratification of MDS patients based on miR-27a-3p and miR-223-3p plasma levels. The cut-off values 
for each miRNA (assessed based on ROC curve analysis), mean PFS and OS values, 95% confidence 
intervals (CIs) and p values are listed for each of the tested variables in Table 10.  
Multivariate Cox analyses confirmed that miR-451a plasma level (cut off 100x104 copies/µl of plasma) 
and amount of cytopenias are associated with PFS and that plasma level of miR-223-3p (cut off 
17x104 copies/µl of plasma) are associated with OS (Table 11). Kaplan-Meier curves (Figure 8) 
showed that patients with low miR-451a expression have significantly decreased PFS (25.7 months, 
95% CI 10.4 to 41.1) compared to those with high expression (41.5 months, 95% CI 29.1 to 54.0) 
and that patients with low miR-223-3p expression have significantly decreased OS (27.7 months, 95% 
CI 13.4 to 41.9 months) compared to those with high expression (70.6 months, 95% CI 57.1 to 84.1 
months). Thus, the results suggest that miR-451a and miR-223-3p may potentially serve as predictive 
biomarkers of patient outcome. 
Further, we performed Pearson correlation analysis for the six selected miRNAs with clinical variables 
(numbers of erythrocytes, platelets, neutrophils, monocytes, leukocytes, and lymphocytes, 
haemoglobin concentration, and percentage of blasts in BM). However, we did not find any 
significant correlation between tested miRNA levels and clinical variables. The absence of correlation 
between miRNA levels and blood cell counts suggests that miRNAs are not simply released from one 
type of blood cells, but their release from cells may be more complex and selective process. 
  
  RESULTS 
64 
 
Table 10. Univariate analysis for PFS and OS. 









95% CI p 
value 
Age < 65 years 26.0 9.5-42.4 .155 52.1 29.9-74.3 .739 
≥ 65 years 35.9 23.3-46.6 42.6 27.6-57.6 
Gender male 36.8 23.3-50.4 .375 46.3 33.0-65.6 .507 
female 23.8 8.6-39.1 49.3 29.4-63.1 
Diagnosis RCUD/ RARS 41.7 19.5-63.9 .038 41.7 19.5-63.9 .958 
RCMD 41.2 24.6-57.8 50.6 32.4-68.9 
RAEB-1/ RAEB-2 13.2 7.5-18.9 26.8 20.1-33.5 
IPSS category lower-risk 42.2 27.9-56.4 .013 50.8 35.2-66.5 .709 
higher-risk 12.7 6.9-18.6 26.3 19.2-33.5 
IPSS karyotype good 42.5 27.9-57.2 .005 53.6 36.8-70.5 .082 
intermediate 24.7 10.6-38.9 42.0 30.7-53.3 
poor 6.4 3.3-9.6 10.2 6.4-13.9 
Blasts < 5% 38.5 24.0-53.0 .191 45.3 28.9-61.7 .314 
≥ 5% 22.0 8.8-35.1 47.6 28.4-66.8 
Haemoglobin < 100 g/l 26.2 12.9-39.5 .082 48.5 29.5-67.5 .699 
≥ 100 g/l 37.0 22.7-51.2 42.3 27.7-57.0 
Neutrophils < 1.5x109/l 29.4 15.1-43.7 .467 40.7 24.1-57.3 .183 
≥ 1.5x109/l 34.5 20.7-48.3 59.7 46.9-72.4 
Platelets < 150x109/l 27.3 15.0-39.5 .126 43.8 26.7-60.7 .179 
≥ 150x109/l 38.8 23.2-54.4 49.6 32.4-66.8 
Cytopenia 0-1 lineage 46.8 31.0-62.5 .024 59.0 49.2-68.7 .084 
2-3 lineages 24.9 13.7-36.1 40.0 23.8-56.2 
miR-16-5p 
 
< 12x104 copies/µl of plasma 25.6 11.4-39.8 .338 49.8 29.1-70.4 .769 
≥ 12x104 copies/µl of plasma 33.6 20.3-47.0 41.8 25.7-58.0 
miR-27a-3p < 2.7x103 copies/µl of plasma 11.2 6.2-16.2 .005 18.0 11.8-24.1 .001 
≥ 2.7x103copies/µl of plasma 41.9 28.0-55.8 60.7 45.7-75.6 
miR-150-5p < 25x103 copies/µl of plasma 26.9 14.0-40.0 .038 44.9 27.6-62.2 .089 
≥ 25x103 copies/µl of plasma 50.1 36.0-64.1 60.0 43.4-76.4 
miR-199a-5p < 2.6x103 copies/µl of plasma 21.9 8.9-34.9 .048 37.9 19.4-56.5 .100 
≥ 2.6x103 copies/µl of plasma 37.4 24.3-50.5 47.6 30.9-64.4 
miR-223-3p < 17x104 copies/µl of plasma 18.3 9.0-27.7 .008 27.7 13.4-41.9 .001 
≥ 17x104 copies/µl of plasma 49.6 32.1-67.2 70.6 57.1-84.1 
miR-451a < 100x104 copies/µl of plasma 25.7 10.4-41.1 .029 56.3 38.6-74.1 .709 
≥ 100x104 copies/µl of plasma 41.5 29.1-54.0 47.6 33.3-61.9 
 
  
  RESULTS 
65 
 
Table 11. Multivariate Cox analysis for PFS and OS. HR – hazard ratio, CI – confidence interval,  
n.a. – not analysed 
 PFS OS 
Variable HR 95% CI p value HR 95% CI p value 
Diagnosis 0.512 0.040-6.488 .300 0.923 0.148-5.744 .932 
IPSS category 6.398 0.835-49.032 .074 1.089 0.089-13.369 .947 
IPSS karyotype 1.207 0.358-4.064 .762 0.151 0.014-1.693 .125 
Cytopenia 12.647 1.578-101.358 .017 2.128 0.172-26.287 .556 
miR-27a-3p  0.177 0.026-1.201 .076 0.682 0.103-4.511 .691 
miR-150-5p  2.983 0.376-23.685 .301 n.a. n.a. n.a. 
miR-199a-5p  4.133 0.527-32.404 .177 n.a. n.a. n.a. 
miR-223-3p  0.739 0.155-3.513 .704 0.039 0.002-0.856 .032 
miR-451a  0.072 0.011-0.467 .006 n.a. n.a. n.a. 
 
 
Figure 8. Patient survival according to miRNA levels. Kaplan-Meier curves for PFS based on miR-451a 
plasma level (p < 0.05) (A) and OS according to miR-223-3p plasma level (p = 0.01) (B). 
 
 
10.1.5 Comparison of circulating miRNA levels with their levels in CD34+ cells 
Previously, we have assessed miRNA profiles in CD34+ MDS cells using microarrays (196). We used 
these data to evaluate the cellular levels of the six miRNAs deregulated in MDS plasma (miR-16-5p, 
miR-27a-3p, miR-150-5p, miR-199a-5p, miR-223-3p, and miR-451a). We observed some expression 
changes between controls, higher-risk, and lower-risk patient groups (Figure 9). However, we did not 
find any apparent relation of circulating miRNA levels to their levels in CD34+ cells, again suggesting  
that miRNA release from cells may be specific process. 




Figure 9.  miRNA levels in CD34+ MDS cells. Relative expression of miR-16-5p, miR-27a-3p,  
miR-150-5p, miR-199a-5p, miR-223-3p, and miR-451a in CD34+ MDS cells were calculated based 
on microarray data (196). CTR – controls, LR – lower-risk, HR – higher-risk MDS patients, * p < 0.05,  
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10.2 Publication 2  
Hrustincova et al., Circulating small noncoding RNAs have specific patterns in plasma 
and extracellular vesicles in myelodysplastic syndromes and are predictive of patient outcome,  
Cells, 2020 
 
In this study, we continued to analyse sncRNA profiles in blood plasma. Notably, we moved from 
microarray profiling to the next generation sequencing (NGS), which provides identification of all 
sncRNAs present in a sample, including non-miRNA sncRNA species. Thus, except for the most 
abundant miRNAs, we detected also other sncRNA species such as piRNAs, tsRNAs, and snoRNAs. 
Importantly, we investigated not only samples of total blood plasma, but also samples of plasma-
derived EVs. It is the very first study in the field of MDS that analyses sncRNA profiles in paired 
samples from two extracellular sources (total plasma and EVs) and draws a comparison between 
them. We identified sncRNAs that may be useful as prognostic and predictive biomarkers of MDS 
outcome and AZA treatment response, respectively.  
In order to keep clarity of this thesis, the large amount of results presented in the publication were 
reduced to only a major link. All the data can be found in the publication and its supplemental 
information. 
 
10.2.1 Patient cohorts 
The study was conducted on 114 blood plasma samples that were randomly divided in two cohorts – 
discovery and validation cohorts. The discovery cohort analysed by NGS comprised 59 individuals, 
including 31 MDS, 11 AML-MRC patients, and 17 healthy controls. Based on the WHO classification 
criteria from 2016 (24), the diagnoses of MDS patients were as follows: 5 MDS-MLD, 5 MDS-RS,  
3 MDS with isolated del(5q), 5 MDS-EB1, and 13 MDS-EB2. The diagnoses MDS-MLD, MDS-RS, 
and MDS with isolated del(5q) were considered early MDS and the diagnoses MDS-EB1 and MDS-EB2 
were considered advanced MDS. The time from diagnosis ranged from zero months (i.e. diagnostic 
samples) to five years from the initial assessment of the diagnosis, with the majority of samples 
obtained within one year from the diagnosis (81 %). The detailed clinical characteristics of all patients 
are summarized in Table 12. An independent validation cohort analysed by ddPCR comprised  
55 individuals, including 36 MDS, 7 AML-MRC patients, and 12 healthy controls (Table 13).  
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Mutational screening for 54 genes associated with myeloid malignancies was done for 18 of 31 MDS 
patients in the discovery cohort (58 %). Of them, 83 % bore at least one somatic mutation with 1.8 
mutational events per patient on average (range 1-5). The most frequently mutated genes 
in the cohort were SF3B1 (5 patients, 28 %, variant allele frequency (VAF) ranging from 26 to 50 %) 
and DNMT3A (5 patients, 28 %, VAF ranging from 26 to 47 %). These two most commonly mutated 
genes were selected for further investigation. 
In the follow-up period, 24 patients received AZA therapy. The mean time from sample collection 
to AZA treatment initiation was 1 month (0-7 months). The mean number of administered AZA cycles 
was 9 (2-56 cycles), the mean time to the best response in the responder cohort was 4.5 months  
(3-6 months), and the mean duration of the response was 15 months (6-56 months). In this AZA 
cohort, 9 patients were considered responders, i.e. they achieved complete remission (CR), partial 
remission (PR), marrow complete remission (mCR), or haematologic improvement (HI), 6 patients 
had stable disease, and 9 patients progressed after AZA treatment initiation. The overall response 
rate (ORR) including rates for all responders within the cohort was 37.5 %. 
Furthermore, we analysed the survival of MDS patients stratified according to clinical variables.  
We found that diagnosis, IPSS-R category, IPSS-R-based karyotype, BM blasts, haemoglobin level, 
and platelet count were significantly associated with OS (univariate analysis, p < 0.05). 
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Table 12. Characteristics of the patients in the discovery cohort. The data are presented as the mean 
and range for all continuous variables.  
MDS 31 
Age (years) 67 (29-87) 




IPSS-R category  
very low/low/intermediate/high/very high/n.a. 
3/10/4/6/6/2 
BM blasts (%) 7.4 (0.4-19.4) 
White blood count (x109/l) 4.3 (1.2-11.9) 
Haemoglobin (g/l) 100 (72-138) 
Neutrophils (x109/l) 2.4 (0.1-8.6) 
Platelets (x109/l) 136 (13-390) 
Cytogenetic features 
          normal karyotype 
          isolated del(5q)  
          complex 
          other 







IPSS-R karyotype  
very good/good/intermediate/poor/very poor/n.a. 
0/18/4/2/4/3 
Somatic mutations 
          No. of analysed patients 
          No. of mutations per patient: 0/1/2/3/4/5 
          The most frequent mutations 
                  SF3B1/DNMT3A/RUNX1/ASXL1/EZH2/SETBP1 
 





          mean follow-up (months) 
22 (1-61) 
Deceased, number of patients 
          mean time to death (months) 
19 (61 %) 
19 (1-43) 
Follow-up treatment with AZA, number of patients 
          No. of responders 
          No. of patients with stable disease 






Age 69 (58-77) 
Sex (male/female) 6/5 
BM blasts (%) 26.0 (20.1-41.0)  
White blood count (x109/l) 3.0 (0.8-8.1) 
Haemoglobin (g/l) 95 (77-127) 
Neutrophils (x109/l) 1.0 (0.1-3.4) 
Platelets (x109/l) 116 (24-258) 
Cytogenetic features 
          normal karyotype 
          isolated del(5q)  
          complex 
          other 







n.a. – not analysed 
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Table 13. Characteristics of the patients in the validation cohort. The data are presented as the mean 
and range for all continuous variables.  
MDS 36 
Age 60 (29-81) 




IPSS-R category  
very low/low/intermediate/high/very high/n.a. 
6/10/5/4/11 
BM blasts (%) 7.1 (0.2-19.8) 
White blood count (x109/l) 3.8 (0.9-11.4) 
Haemoglobin (g/l) 101 (59-138) 
Neutrophils (x109/l) 1.8 (0.1-7.6) 
Platelets (x109/l) 126 (26-273) 
Cytogenetic features 
          normal karyotype 
          isolated del(5q)  
          complex 






IPSS-R karyotype  
very good/good/intermediate/poor/very poor 
1/20/3/3/9 
Follow-up 
          mean follow-up (months) 
11 (0-77) 
Deceased, number of patients 
          mean time to death (months) 
17 (47 %) 
7 (1-23) 
AML-MRC 7 
Age 68 (62-76) 
Sex (male/female) 5/2 
BM blasts (%) 36.3 (23.0-62.0)  
White blood count (x109/l) 2.2 (1.0-4.8) 
Haemoglobin (g/l) 100 (85-127) 
Neutrophils (x109/l) 0.8 (0.1-2.9) 
Platelets (x109/l) 91 (10-202) 
Cytogenetic features 
          normal karyotype 
          complex 





n.a. - not analysed 
 
10.2.2 Characterization of extracellular vesicles in MDS plasma 
To characterize the EVs in MDS plasma, we analysed several total plasma samples by nanoparticle 
tracking analysis (NTA). We observed that neither particle counts, nor their cumulative volumes were 
associated with the disease. However, we observed a fraction of particles with larger sizes specifically 
in the plasma of higher-risk MDS patients (Figure 10, A and B). More importantly, we obtained 
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significantly higher amounts of RNA material from patient samples compared to controls when 
isolated from total plasma samples (44.7 ± 3.2 ng/ml of plasma in controls vs. 92.9 ± 8.8 ng/ml 
in patient samples, p = 0.01) as well as from EV fractions (7.3 ± 0.5 ng/ml of plasma in controls  
vs. 17.5 ± 1.3 ng/ml in patient samples, p = 0.0005) (Figure 10C). 
 
Figure 10. Characterization of extracellular particles in plasma. (A) Particle size (mean size with 10th 
and 90th percentiles) measured by nanoparticle tracking analysis (NTA). (B) NTA report 
of representative samples of total plasma from one control and one MDS-EB2 patient. (C) RNA yield 
obtained from (a) 1 ml of total plasma and (b) EV samples that were isolated from 1 ml of the plasma 
is plotted. 
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After separation, we reanalysed the isolated EVs by transmission electron microscopy (TEM), NTA, 
and western blotting. TEM imaging showed that the majority of isolated EVs ranged in size from 
50 nm to 100 nm, suggesting sufficient exosome enrichment in the samples (Figure 11A). Based 
on the NTA measurements, we determined that the obtained EVs had a mode size of 96 nm (the size 
that has the highest number of recurrences in the sample), with particle sizes ranging from 87 to 180 
nm (10th to 90th percentile) (Figure 11B). Using western blotting, we confirmed the presence 
of exosomes. Common exosome markers CD9 and CD81 were detected in MDS and control EV 
samples, whereas cell organelle (endoplasmic reticulum) marker calnexin tested as a negative control 
was not detected (Figure 11C). Based on these data, we conclude that although enriched 
in exosomes, our precipitated EV fractions contain a heterogeneous mixture of exosomes and,  
to a lesser extent, microvesicles. This is consistent with outputs from other protocols including those 
based on high-speed ultracentrifugation, e.g. (238). 
 
Figure 11. Transmission electron microscopy (TEM) (A) and nanoparticle tracking analysis (NTA) (B) of 
one representative EV sample. Characterization of exosomes in EV samples by western blotting (C). 
Common exosome markers CD9, CD81, and cell organelle marker calnexin (negative control). K562 
Total Cell Lysate (TCL) was loaded as a control.  
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10.2.3 General overview of circulating sncRNAs in MDS patients 
To systematically characterize the sncRNAs circulating in MDS plasma, we performed small RNA-seq 
analysis in paired samples (118 samples from 59 individuals) of total plasma and plasma-derived EVs. 
On average, we captured 8.3 millions (M) of total reads per sample (4.0-18.0 M reads) 
and after filtering, 5.0 M reads on average per sample (2.6-12.6 M reads) were retained 
in the analysis. In the filtering process, we removed all reads that had low quality scores, defective 
or missing adapters and/or barcodes, and were shorter than 16 nucleotides. The data have been 
deposited in the SRA (Sequence Read Archive) database under accession no. PRJNA574254. 
The retained sequences were annotated and assigned to several categories of transcripts. The most 
abundant categories of transcripts were miRNAs (51.0 % of reads on average), followed by rRNAs  
(4.1 %), piRNAs (0.7 %), tRNAs (0.4 %), and mRNAs (0.4 %). Of the retained reads, 42.2 % were 
uncharacterized (of these, 8.5 % were mappable and 33.7 % were not mappable to the human 
genome). In total, we identified 2,543 miRNAs, 141 piRNAs and 364 tRNAs with at least one read 
in one sample. 
Because a large proportion of the mapped reads were uncharacterized, we predicted potential 
de novo miRNAs among these sequences. Using the miRdeep2 tool, we identified 7,667 de novo 
miRNAs in total. On average, we found 168 and 146 de novo miRNAs per sample of total plasma and 
EVs, respectively. These de novo identified miRNAs were included in subsequent differential 
analyses.  
Furthermore, we addressed the question of the features and origin of the uncharacterized 
unmapped reads. Interestingly, their proportion increased with read length. While almost all 
of the reads with lengths of 20-22 bp mapped to the human genome, the unmapped reads were 
longer  
( > 31 bp). A high percentage of unmapped sequences was annotated as 16S/18S rRNA molecules 
of nonhuman origin (approx. 20 %), suggesting that numerous RNAs originating from other species 
are present in human plasma. The majority of these reads were mappable to Proteobacteria, 
Ascomycota, Streptophyta, and Chlorophyta. No apparent profile specific to MDS patients either 
in total plasma or in EVs was found (Figure 12). However, a deeper analysis of these nonhuman 
sequences with respect to differential representation of individual taxa has not been done as is 
beyond the scope of this study. 
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Figure 12. Taxonomy profile of reads mappable to nonhuman genomes. The proportion of the reads 
assigned to individual phyla is shown. 
 
 
10.2.4 Comparison of total plasma samples with EV samples 
We focused on human sncRNAs and observed that total plasma samples had a substantially higher 
proportion of miRNA reads compared to EV samples (60 % in total plasma and 46 % in EVs 
on average). In contrast, EV samples had higher proportion of uncharacterized reads than total 
plasma samples (38 % in EVs and 27 % in total plasma on average). Hierarchical cluster analysis of all 
samples revealed that EV content was more homogeneous than the sncRNA content of total plasma, 
preferentially clustering the majority of EV samples into one cluster (Figure 13).  
Further, we performed differential expression analysis between paired samples of total plasma and 
EVs. We identified a striking difference between MDS and control samples. In MDS samples, 419 
sncRNAs were differentially represented between total plasma and EVs (|logFC| > 1 and q < 0.05). 
In controls, only 44 sncRNAs reached this statistical significance cut off and the majority of them 
were also found in MDS samples. However, 385 differentially represented sncRNAs between total 
plasma and EVs were uniquely identified only in MDS. Interestingly, levels of miRNAs were 
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proportionally deregulated between the two materials (114 miRNAs were increased in total plasma 
and 105 miRNAs were increased in EVs), but the levels of piRNAs, tRNAs, and other RNA categories 
were almost exclusively increased in total plasma (25 piRNAs and 105 tRNAs were increased in total 
plasma and only four piRNAs and three tRNAs were increased in EVs). These data suggest substantial 
deregulation of circulating sncRNAs associated with MDS. Moreover, the process of RNA release 
from cells may be specific for distinct sncRNA species, for example particular sncRNA species may be 
selectively loaded into EVs.  
 
Figure 13. Hierarchical cluster analysis of total plasma and EV samples based on all RNA-seq data. 
The blue frame highlights the clustered EV samples. CTR – controls, PTS – MDS/AML-MRC patients 
 
 
10.2.5 sncRNAs differentially expressed in MDS 
To characterize sncRNA profiles specific for MDS, we compared sncRNA levels between MDS 
patients, AML-MRC patients, and controls in each material separately. The results show relatively 
higher numbers of differentially represented sncRNAs (|logFC| > 1 and q < 0.05) between MDS 
patients and controls in total plasma (391 sncRNAs with 316 increased and 75 decreased sncRNAs 
in MDS) than in EVs (219 sncRNAs with 179 increased and 40 decreased sncRNAs in MDS). Table 14 
shows the distribution of deregulated sncRNAs among various sncRNA species. Many of these 
sncRNAs were uniquely deregulated either in total plasma or EVs. Importantly, we found that 
the levels of many haematopoiesis-related miRNAs were significantly increased (q < 0.05) in MDS 
patients compared to controls, mostly in both plasma and EVs (e.g. miR-10a-5p, miR-29a-3p,  
miR-34a-5p, miR-99b-5p, miR-125a-5p, miR-146b-5p, and miR-150-3p/5p were increased in both 
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total plasma and EVs, and let-7a-3p, miR-21-3p, miR-221-3p, miR-221-3p/5p, and miR-223-3p were 
increased only in total plasma). Regarding other types of sncRNAs, hsa_piR_019914/gb/DQ597347, 
hsa_piR_020450/gb/DQ598104, chr2.trna27-GlyCCC, chr18.trna4-LysCTT, SNORD119, and U33 were 
upregulated in MDS samples (q < 0.05). 
On the other hand, there were almost no significant differences between sncRNA profiles of MDS 
and AML-MRC patients. There were only 9 and 14 differentially represented RNAs in plasma and EVs, 
respectively (Table 15). 
 
Table 14. Numbers of significantly deregulated (|logFC| > 1 and q < 0.05) circulating sncRNAs in MDS 
patients compared to controls. 
Type of transcripts total plasma EVs 
increased decreased increased decreased 
all annotated RNAs 316 75 179 40 
annotated miRNAs 112 36 65 18 
de novo identified miRNAs 19 39 26 20 
piRNAs 24 0 15 1 
tRNAs 120 0 43 1 
other annotated RNAs 41 0 30 0 
 
 
Table 15. Numbers of significantly deregulated (|logFC| > 1 and q < 0.05) circulating sncRNAs in MDS 
patients compared to AML-MRC patients. 
Type of transcripts total plasma EVs 
increased decreased increased decreased 
all annotated RNAs 1 8 0 14 
annotated miRNAs 0 3 0 1 
de novo identified miRNAs 1 5 0 10 
piRNAs 0 0 0 1 
tRNAs 0 0 0 2 
other annotated RNAs 0 0 0 0 
 
 
10.2.6 sncRNAs differentially expressed between early and advanced stages of MDS 
To define sncRNAs with changed levels during MDS progression, we investigated the differences 
in sncRNA profiles between early (MDS-MLD, MDS-RS, and MDS with isolated del(5q)) and advanced 
stages of MDS (MDS-EB1 and MDS-EB2). These results showed 100 and 43 differentially represented 
sncRNAs (|logFC| > 1 and q < 0.05) in plasma (81 increased and 19 decreased in early MDS) and EVs 
  RESULTS 
77 
 
(34 increased and 9 decreased in early MDS), respectively. Their distribution among various sncRNA 
species is shown in Table 16. Heatmaps in Figure 14 show apparently distinct levels of these sncRNAs 
associated with the stage of the disease when the patients are divided according to either WHO 
classification or IPSS-R score.  
The detailed examination of significantly deregulated sncRNAs (|logFC| > 1 and q < 0.05) between 
early and advanced stages of MDS revealed that only 14 sncRNAs were deregulated in both types 
of materials, total plasma and EVs. Regarding haematopoiesis related miRNAs, levels of some 
of them (e.g. miR-103a-3p, miR-103b, miR-107, miR-221-3p, miR-221-5p, and miR-130b-5p) were 
significantly decreased (q < 0.05) in total plasma of advanced MDS compared to early MDS. 
Interestingly, multiple miRNAs (e.g. miR-127-3p, miR-154-5p, miR-323b-3p, miR-382-3p, miR-409-5p, 
and miR-485-3p) clustered in chromosomal region 14q32 were found among the significantly 
upregulated (q < 0.05)  miRNAs in total plasma and/or EVs of early MDS. Regarding other sncRNA 
species, hsa_piR_000805/gb/DQ571003, hsa_piR_019420/gb/DQ596670, chr6.trna152-ValCAC, 
and chr7.trna5-CysGCA were significantly deregulated (q < 0.05) between early and advanced MDS. 
 
Table 16. Numbers of significantly deregulated (|logFC| > 1 and q < 0.05) circulating sncRNAs in early 
MDS patients compared to advanced MDS patients. 
Type of transcripts total plasma EVs 
increased decreased increased decreased 
all annotated RNAs 81 19 34 9 
annotated miRNAs 55 12 24 7 
de novo identified miRNAs 12 4 8 0 
piRNAs 7 1 1 2 
tRNAs 5 1 1 0 
other annotated RNAs 2 1 0 0 
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Figure 14. Heatmaps of differentially represented sncRNAs between early and advanced MDS in total 
plasma (left) and EVs (right) (q < 0.05). Color gradient intensity scale shows the row z-score of CPM 
(binary logarithm) of individual RNAs. Red indicates increased level of RNA, blue indicates decreased 
level of RNA. Each column represents a patient, and each row represents an RNA. 
 
 
10.2.7 Quantification of individual sncRNA levels by ddPCR 
To validate the results of NGS analysis, we evaluated the levels of miR-16-5p, miR-34a-5p,  
miR-125a-5p, miR-125b-5p, miR-127-3p, miR-221-3p, and hsa_piR_001170/DQ571526 by ddPCR 
in an independent validation cohort (36 MDS patients, 7 AML-MRC patients, and 12 controls, Table 
13). These sncRNAs were selected based on their previously described relevance for MDS  
and/or significantly different levels in the small RNA-seq experiments. After absolute quantification 
of sncRNA levels, we compared these results with those of the small RNA-seq analysis by performing 
Pearson correlation of the mean expression values measured in the individual sample groups 
(controls, early MDS, advanced MDS, and AML-MRC). The correlation analysis proved concordance 
between both methods (r = 0.606, p = 0.0001) as shown in Figure 15. 
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Figure 15. Correlation of sncRNA levels measured by different methods in two independent sample 
cohorts. In the testing cohort, the data were obtained using small RNA-seq (NGS) and  
in the validation cohort, by ddPCR method. (A) The mean values of sncRNA levels (miR-16-5p,  
miR-34a-5p, miR-125a-5p, miR-125b-5p, miR-127-3p, miR-221-3p, and hsa_piR_001170/DQ571526) 
in individual sample groups (controls, early MDS, advanced MDS, and AML-MRC) were plotted  
in the graph and Pearson correlation was calculated. (B) Detailed comparison of NGS and ddPCR 




10.2.8 Pathway analysis based on miRNA profiles specific for MDS 
To identify biological functions potentially influenced by deregulated miRNAs circulating in MDS 
plasma, we performed miRNA target prediction coupled with pathway enrichment analysis. 
The analyses were performed for miRNAs differentially represented (|logFC| > 1, q < 0.05) between 
MDS and control samples, and between early and advanced MDS samples either in plasma or EVs. 
As shown in Table 17 and Table 18 in more detail, we found that the deregulated miRNAs were 
associated with multiple pathways related to cancer (namely, the Ras, TGF-beta, ErbB, and Rap1 
pathways), pluripotency of stem cells, extracellular matrix (ECM), and focal adhesion. 
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Table 17. The most significantly enriched pathways in the sets of deregulated miRNAs between MDS 
and controls. The top ten pathways with the most significant p values are listed for each dataset. 
 
KEGG pathway p value 
plasma: MDS vs. CTR   
Mucin type O-Glycan biosynthesis 9.77e-15 
Proteoglycans in cancer 6.05e-09 
ErbB signalling pathway 2.80e-08 
Ras signalling pathway 2.02e-07 
Axon guidance 2.02e-05 
Pathways in cancer 2.02e-05 
Rap1 signalling pathway 3.30e-05 
Lysine degradation 3.33e-05 
Glioma 6.23e-05 
Signalling pathways regulating pluripotency of stem cells 9.51e-05 
EVs: MDS vs. CTR   
ECM-receptor interaction 1.16e-26 
Fatty acid biosynthesis 1.41e-08 
ErbB signalling pathway 1.41e-08 
Proteoglycans in cancer 1.57e-08 
Axon guidance 3.54e-08 
Glioma 5.42e-08 
Mucin type O-Glycan biosynthesis 5.18e-06 
Estrogen signalling pathway 3.52e-05 
Focal adhesion 5.71e-05 
Signalling pathways regulating pluripotency of stem cells 5.71e-05 
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Table 18. The most significantly enriched pathways in the sets of deregulated miRNAs between early 
and advanced MDS. The top ten pathways with the most significant p values are listed for each 
dataset. 
 
KEGG pathway p value 
plasma: early vs. advanced MDS  
Amphetamine addiction 1.56e-07 
Signalling pathways regulating pluripotency of stem cells 5.60e-06 
Transcriptional misregulation in cancer 1.35e-05 
Gap junction 2.31e-05 
Glioma 3.38e-05 
FoxO signalling pathway 5.34e-05 
Hippo signalling pathway 0.000116 
ErbB signalling pathway 0.000172 
Proteoglycans in cancer 0.000175 
TGF-beta signalling pathway 0.000254 
EVs: early vs. advanced MDS  
Biotin metabolism 0.00716 
Central carbon metabolism in cancer 0.00716 
Signalling pathways regulating pluripotency of stem cells 0.00716 
Lysine degradation 0.00983 
TGF-beta signalling pathway 0.00983 
Steroid biosynthesis 0.0129 
Glioma 0.0139 
RNA transport 0.0141 
ErbB signalling pathway 0.0145 
Morphine addiction 0.0145 
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10.2.9 Relation between somatic mutations and levels of circulating sncRNAs in MDS 
We explored the possible relation between the presence of somatic mutations and the levels 
of circulating sncRNAs in MDS. Using differential expression analyses, we searched for sncRNAs 
with differential expression between MDS patients with vs. without a mutation in SF3B1 or DNMT3A 
genes. The analysis identified only a few significantly deregulated sncRNAs (SF3B1: no sncRNAs, 
DNMT3A: miR-7515 in total plasma, miR-6857-3p, miR-9-3p, and hsa_piR_020485/gb/DQ598159 
in EVs, p < 0.05, Figure 16A). 
To gain better insight into the potential effects of SF3B1 and DNMT3A mutations on levels 
of circulating sncRNAs, we refined the selection criteria and included all sncRNAs at raw p < 0.01 
(non-adjusted for multiple testing) with the awareness of potential high numbers of false positive 
results. Regarding the SF3B1 mutations, we identified 22 and 15 sncRNAs deregulated in total plasma 
and EVs, respectively. The DNMT3A mutations were associated with the deregulation of 34 sncRNAs 
in total plasma and 32 sncRNAs in EVs (p < 0.01). Finally, we intersected deregulated sncRNAs  
in the two materials and found that total plasma and EVs displayed different sncRNA profiles. Only 
miR-100-5p and miR-450b-5p of SF3B1-mutated samples were deregulated in both materials, plasma 
and EVs (Figure 16B). 
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Figure 16. Differential sncRNA levels associated with presence of somatic mutations in (A) DNMT3A 
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10.2.10 Circulating sncRNAs as prognostic biomarkers of MDS survival 
The OS‐associated sncRNAs were identified by performing univariate Cox regression along 
with a permutation test using BRB‐ArrayTools (239). sncRNAs with permutation p values < 0.001, 
which were computed based on 10,000 random permutations, were considered significantly 
associated with survival. Two sets of sncRNAs (separately for the two materials, total plasma 
and EVs) whose levels significantly correlated with OS were identified. Of the 3,130 sncRNAs 
uploaded into the analysis tool, 173 and 122 sncRNAs were significantly (univariate p < 0.05) 
associated with OS in total plasma and EVs, respectively. Of these, only the sncRNAs with the highest 
level of association (permutation p < 0.001) were chosen for further analyses, i.e. three sncRNAs 
in total plasma (miR-1260b, miR-3191-3p, and miR-328-3p) and four sncRNAs in EVs (miR-1237-3p, 
U33, hsa_piR_019420/gb/DQ596670, and miR-548av-5p). The results are summarized in Table 19 
and Kaplan-Meier plots are shown in Figure 17. 
To test the combination strategy of multiple survival-associated sncRNAs for better patient 
stratification, we defined a risk prediction score that combined the effects of the selected sncRNAs 
above. A formula of survival risk score was constructed by including each of the selected sncRNAs, 
weighted by their estimated regression coefficients in the univariate Cox regression model. 
The leave‐one‐out cross‐validation (LOOCV) method was employed to evaluate the accuracy  
of the score system. The prognostic index of sample was computed by the formula ∑iwi xi + C, where 
wi is the estimated regression coefficient, xi is the logged level for the i-th gene, and C is a coefficient 
for recalculation of the final index to zero.  
The coefficients of survival risk formula for these individual sncRNAs contributing to final risk 
assessment and p values of cross-validation tests are included in Table 19. The final survival risk score 
of a total plasma sample was calculated based on the following formula: 
Plasma risk score = - 0.631 × log2 (level of miR-1260b) - 0.24 × log2 (level of miR-328-3p) + 6.861. 
Similarly, the survival risk score of an EV sample was calculated as follows: 
EV risk score = 0.615 × log2 (level of miR-1237-3p) + 0.917 × log2 (level of U33) - 0.106 × log2  
(level of hsa_piR_019420) - 1.01 × log2 (level of miR-548av-5p) - 4.948. 
A higher score (> 0) indicated an increased risk of mortality, whereas a lower score ( ≤ 0) denoted 
a better outcome. Thus, the patient cohort was partitioned into two risk groups according  
to the survival risk score (> 0 for the higher‐risk group and ≤ 0 for the lower‐risk group). 
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To evaluate the performance of combined prognostic signatures, Kaplan-Meier curves and receiver 
operation characteristic (ROC) curves were plotted for the samples divided into higher-risk 
and lower-risk groups according to the computed score formulas. The results showed that combining 
sncRNA level scores increased the predictive power of the survival risk model more significantly in EV 
material (univariate p < 0.001, ROC: AUC = 0.860, p = 0.0009) than in total plasma (univariate  
p = 0.008, ROC: AUC = 0.636, p = 0.206) as shown in Figure 18. 
Furthermore, we tested the relation between individual survival-associated sncRNAs and their 
combination scores with clinical parameters. A series of Pearson correlation tests showed 
a significant association between the levels of the majority of these sncRNAs and BM blast count 
and platelet count (Table 20). However, Cox multivariate analysis revealed that the EV combined 
score (HR = 5.866, 95% CI 2.262 to 15.210, p < 0.001) was the variable most significantly associated 
with OS, even when compared with the IPSS-R score (HR = 1.410, 95% CI 0.840 to 2.366, p = 0.193) 
(Table 21). 
 
Table 19. sncRNAs associated with OS of MDS patients. Prediction model coefficients are applicable 
to the formula of survival risk score. The survival risk score of a total plasma sample = - 0.631 × log2 
(level of miR-1260b) - 0.24 × log2 (level of miR-328-3p) + 6.861. Similarly, the survival risk score of an 
EV sample = 0.615 × log2 (level of miR-1237-3p) + 0.917 × log2 (level of U33) - 0.106 × log2 (level 
of hsa_piR_019420) - 1.01 × log2 (level of miR-548av-5p) - 4.948. A sample is predicted as high (low) 
risk if its prognostic index is > 0 (≤ 0). n.a. – not applicable, n.s. – nonsignificant 










miR-1260b 0.0007 0.0006  0.441 -0.631 0.0002 
miR-3191-3p 0.0009 0.0009 0.338 n.a. n.s. 
miR-328-3p 0.0009 0.0008 0.474 -0.24 0.0008 
EV fraction 
miR-1237-3p 0.00002 < 1e-07 20.135 0.615  5e-07 
U33 0.0006 0.0006 2.499 0.917  0.0002 
hsa_piR_019420 0.001 < 1e-07 20.135 -0.106  0.0008 
miR-548av-5p 0.001 0.001 0.217 -1.01 0.0009 
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Figure 17. Kaplan-Meier curves for individual sncRNAs significantly associated with OS of MDS 
patients in samples of (A) total plasma and (B) EVs. 
 
 
Figure 18. Performance of the combined prognostic model for OS of MDS patients. Kaplan-Meier 
curves and ROC curves are shown for (A) a two-sncRNA signature (miR-1260b and miR-328-3p) 
in total plasma and (B) a four-sncRNA signature (miR-1237-3p, U33, hsa_piR_019420,  
and miR-548av-5p) in EVs. 
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Table 20. Correlation of clinical variables with individual sncRNA levels and with combined scores 
for OS. The Pearson correlation coefficient is listed. *** p < 0.001, ** p < 0.01, * p < 0.05. 
  age blasts haemoglobin neutrophils platelets karyotype 
Total 
plasma 
miR-1260b -0.334 -0.510** 0.046 0.015 0.838*** -0.225 
miR-3191-3p -0.253 -0.199 -0.125 0.061 0.337 -0.300 
miR-328-3p -0.453* -0.487** 0.239 0.029 0.826*** -0.203 
combined score (total plasma) 0.284 0.531** -0.088 -0.053 -0.818*** 0.218 
EVs 
U33 0.090 0.365* -0.229 0.146 -0.372* -0.093 
hsa_piR_019420/DQ596670 0.090 0.412* -0.119 0.140 -0.473** -0.053 
miR-548av-5p 0.045 -0.207 0.357* -0.114 0.270 -0.204 
combined score (EVs) 0.168 0.413* -0.374* 0.066 -0.490** 0.264 
 
 
Table 21. Cox multivariate analysis for OS of MDS patients. 
variable HR 95.0% CI for HR p value 
Lower Upper 
age 1.044 0.945 1.153 0.397 
blasts 0.882 0.767 1.013 0.076 
haemoglobin 1.001 0.961 1.043 0.948 
neutrophils 0.778 0.577 1.048 0.099 
platelets 1.003 0.993 1.013 0.602 
IPSS-R score 1.410 0.840 2.366 0.193 
combined score (total plasma) 1.764 0.666 4.677 0.254 
combined score (EVs) 5.866 2.262 15.210 < 0.001 
 
 
10.2.11 Circulating sncRNAs predictive of response to AZA therapy 
To search for sncRNAs applicable as predictive biomarkers of the AZA treatment response,  
we analysed RNA-seq data from AZA-treated MDS/AML-MRC patients. Using differential expression 
analysis, we found only a few sncRNAs significantly (|logFC| > 1, q < 0.05) associated with patient 
response to AZA. In total plasma, the levels of miR-4774-3p and miR-762 were increased, 
and the levels of miR-125b-5p, miR-4324, miR-3156-5p, and miR-3692-3p were decreased in relation 
to later response to AZA treatment. In EVs, different sncRNAs were associated with AZA response. 
Levels of miR-6857-3p, miR-1299, miR-183-5p and miR-513b-3p were increased, and miR-6832-3p 
levels were decreased. 
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Because the results of differential expression analysis were limited to only several miRNAs of low 
predictive value, we performed additional machine learning analysis (with support of Jiří Kléma, 
Czech Technical University, Prague) to define a combined sncRNA signature that would predict 
the AZA response with higher accuracy compared to individual sncRNAs. The Recursive Feature 
Elimination (RFE) method implemented in Support Vector Machine (SVM) regression model was used 
to define sncRNA classifiers that discriminated AZA responders and nonresponders based on sncRNA 
pretreatment levels and interactions between them. Accuracy (Acc) and AUC were calculated 
to define the optimal number of features. Since the data sample was limited, the LOOCV method was 
employed to provide an unbiased evaluation of a model fit. The group of best classifiers was further 
tested and reduced by backward stepwise logistic regression algorithms using the maximum 
likelihood estimation (MLE) method. The resulting predictive formula was calculated by logistic 
regression using the KNIME platform and sag solver. 
The results from the SVM-RFE regression model showed that the best classification of responders  
vs. progressors could be achieved using cumulative expression data of five sncRNAs measured 
in total plasma (AUC = 0.815, Acc = 0.778), with 6 to 10 sncRNAs combined being of less predictive 
value (Figure 19, A and B). The five most common sncRNAs with the best cumulative predictive value 
determined by SVM were miR-423-5p, miR-126-3p, miR-151a-3p, miR-125a-5p, and miR-199a-3p 
(Figure 19C). These results, however, were achieved only for the total plasma and for the clearly 
defined groups of patients (responders vs. progressors). When testing the data from EV samples 
or trials involving patients with stable disease after AZA treatment, no significant differences were 
detected. 
The sncRNAs preselected by differential expression analysis (miR-125b-5p, miR-4324,  
and miR-4774-3p) and the sncRNAs with the best cumulative predictive value in the SVM model  
(miR-423-5p, miR-126-3p, miR-151a-3p, miR-125a-5p, miR-199a-3p, miR-142-5p, Ro-associated RNA, 
miR-185-5p, miR-30d-5p, miR-92a-3p, let-7a-5p, let-7f-5p and miR-26b-5p) for total plasma samples 
of responders vs. progressors were further statistically tested together by logistic regression analysis 
using maximum likelihood estimation, and their number was reduced to five (miR-423-5p,  
miR-126-3p, miR-151a-3p, miR-125a-5p, and miR-199a-3p), which was in agreement with the SVM 
method. The following predictive formula was calculated with these five miRNAs (Figure 19D): 
Prediction score = 2.629 × ln(level of miR-423-5p) - 2.471 × ln(level of miR-126-3p) + 0.427 x ln(level 
of miR-151a-3p) – 0.203 x ln(level of miR-125a-5p) – 0.1 x ln(level of miR-199a-3p) + 0.808. 
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A score > 0 predicted future response to AZA, whereas a score ≤ 0 predicted progression  
of the disease despite AZA treatment. The quality of the prediction was 88.9 % (16 out of 18 
patients). 
 
Figure 19. Combined prediction model for response to AZA treatment in MDS/AML-MRC patients.  
(A) Results of the SVM-RFE regression model determining the optimal number of sncRNAs whose 
combined expression could be predictive of the likelihood of response. (B) ROC curve for the five 
sncRNA predictors. (C) Total plasma levels of the best/most common predictors (miR-423-5p,  
miR-126-3p, miR-151a-3p, miR-125a-5p, and miR-199a-3p). (D) Coefficients for calculation 
of predictive formula for AZA treatment response. AUC – area under the ROC curve, Acc – accuracy 
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10.3 Publication 3 
Krejcik et al., MicroRNA profiles as predictive markers of response to azacitidine therapy 
in myelodysplastic syndromes and acute myeloid leukaemia, Cancer Biomarkers, 2018 
 
In this study, we focused on intracellular miRNA profiles in BM samples in order to search 
for potential miRNA biomarkers that would predict patient responsiveness to AZA therapy. We found 
that responders and nonresponders show distinct miRNA profiles and that the pretreatment levels 
of specific miRNAs may predict patient response to AZA therapy. 
 
10.3.1 Patient cohort 
The study was conducted on a cohort of 27 patients (19 MDS and 8 AML-MRC patients) and 11 
healthy controls. Based on the WHO classification criteria from 2008 (23), the diagnoses of MDS 
patients are as follows: 1 MDS patient with RCMD, 2 MDS patients with RAEB-1, and 16 MDS patients 
with RAEB-2. The detailed clinical characteristics of all patients are summarized in Table 22.  
Altogether, the study included 50 samples from 27 patients with MDS/AML-MRC at baseline  
(i.e. patients before AZA administration) and during AZA therapy (collected at the time of the best 
response, between cycles 4 and 11). Serial samples (i.e. samples taken from one patient at baseline 
and during the therapy) were available for 23 patients, four patients were screened only before AZA 
therapy. The microarray profiling was performed on a discovery cohort that comprised of 28 samples 
including serial samples from 12 patients prior to and during AZA therapy and four control samples. 
The validation cohort analysed by RT-qPCR included all 50 patient samples and 11 control samples. 
The median number of administered AZA cycles was eight (range, 3-34 cycles), the median time 
to the best response in the responder cohort was five months (range, 3.2-11.0 months),  
and the median duration of response was 16.8 months (range, 8.0-29.1 months). ORR that included 
rates for all responders was 40 % within the cohort. The responses were complete remission (CR) 
in four cases (15 %), partial remission (PR) in three cases (11 %), marrow CR (mCR) in two cases (7 %), 
and haematologic improvement (HI) in two cases (7 %). The nonresponders (60 %) consisted of eight 
patients with stable disease (SD, 30 %) and eight patients with progressed disease (PD, 30 %). 
The median patient follow-up from the initiation of AZA treatment was 21.1 months (range, 3.4-47.1 
months), 25 patients died and two patients were censored at the time of last follow-up. The OS was 
defined as the time from the beginning of treatment until death from any cause or the last follow-up. 
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Based on Cox-regression analysis, the responders and nonresponders showed significantly different 
OS (hazard ratio [HR] = 0.195, 95 % confidence interval [CI], 0.070 to 0.542, p < 0.01).  
 
Table 22. Characteristics of the patients. The data are presented as the median and range for all 
continuous variables.  
Patients 19 MDS 
8 AML-MRC 
Age 68 (63-82) 





BM blasts 18 (4-27) 
Karyotype                                                                                                                                                                     
           Isolated del(5q) / del(5q) + any other abnormality 5/10 
           Isolated trisomy 8 / trisomy 8 + any other abnormality 2/5 
           Normal 8 
Cytogenetics by IPSS-R*             
good/intermediate/poor/very poor/n.a.                                                                                                                                                       
    
17/6/1/2/1                                                                                                                                                         
IPSS-R (MDS patients only)        
intermediate/high/very high                                                                                                                                                             
            
5/9/5                                                                   
AZA cycles administered 8 (3-34) 
Follow-up (months) 21.1 (3.4-47.1) 
Alive                                                                                                                                                                    2 (7 %)
Response                                                                                                                                                                        
           complete remission 4 (15 %) 
           partial remission 3 (11 %) 
           marrow complete remission 2 (7 %) 
           haematologic improvement 2 (7 %) 
           stable disease 8 (30 %) 
           progressed disease 8 (30 %) 
Overall response rate                                                                                                                                                             11 (40 %) 
n.a. – not available  
* The IPSS-R cytogenetic risk score has been established for patients with MDS and is not commonly 
used to stratify AML patients. However, we used this score for both MDS and AML patients,  
with the aim to compare frequencies of karyotypes across these patient groups. 
 
10.3.2 miRNA profiling in samples at baseline 
miRNA profiling was performed on selected samples from 12 patients at baseline and 4 controls 
using microarrays. ANOVA identified 64 differentially expressed miRNAs (p < 0.05) in samples 
at baseline, which were stratified according to their later response status (three CR, two PR, four SD, 
and three PD patient samples) as shown in Figure 20. Hierarchical clustering of these miRNAs clearly 
defined four sample clusters with different miRNA profiles: i) controls, ii) patients with CR,  
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iii) patients with PR, and iv) a mixed cluster of nonresponders (SD and PD). The baseline  
samples obtained from patients who later achieved CR exhibited the most distinct profile  
with the downregulation of let-7c, miR-27b-3p, miR-100-5p, mir-140-3p, and miR-423-5p 
and upregulation of miR-21-5p, miR-211-3p, miR-1246, miR-5739, miR-6085, miR-6124, miR-6132, 
and miR-6165. In nonresponders, significant downregulation of miR-10a/b-5p and upregulation 
of miR-1 and miR-133b were observed compared to patients with CR and PR.  
For all subsequent analyses, patients were divided in the two groups of responders 
and nonresponders, because the study comprised limited number of samples and no significant 
differences in miRNA profiles between SD and PD samples were found. 
 
10.3.3 miRNA profiling in samples before and during AZA therpy 
To identify the miRNAs affected by AZA therapy, miRNA expression profiles in samples at baseline 
and during AZA treatment from 12 patients were compared by paired t-tests. miRNAs with median 
expression level change of 30 % and more (p < 0.05) compared to their level at baseline included 
20 downregulated (i.e. let-7f-5p/7g-5p, miR-10a-5p, miR-142-3p, miR-146a-5p, miR-148a-3p,  
miR-181a-3p/b-5p/c-5p, miR-196b-5p, and miR-451a) and 14 upregulated miRNAs (i.e. miR-1202, 
miR-1260a, and miR-3656) in all tested patients irrespective of their response status (Figure 21). 
To determine the miRNAs involved in response to AZA therapy, miRNA expression levels after AZA 
treatment in responders and nonresponders were compared. 30 miRNAs with significantly different 
expression levels (p < 0.05) in responders along with unchanged levels in nonresponders were found 
(Figure 22). Among these, miR-10b-5p, miR-15a-5p/b-5p, miR-24-3p, miR-148b-3p, and miR-199a-3p 
were downregulated and miR-1202 or miR-1260a were upregulated in responders after AZA 
treatment compared to the baseline samples. 
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Figure 20. Differentially expressed miRNAs in the baseline samples. The heatmap shows altered 
miRNA expression (p < 0.05) between sample groups with different response status. Color gradient 
intensity scale indicates logFC of signal intensities compared with the mean signal intensity 
of controls. Red indicates an increased level of RNA, blue indicates a decreased level of RNA.  
Each column represents a patient, and each row represents a miRNA. CTR – control, CR – complete 
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Figure 21. Differentially expressed miRNAs after AZA treatment irrespective to patient response 
status. The heatmap shows altered miRNA expression in samples after AZA treatment compared 
to paired samples at baseline. Color gradient intensity scale indicates logFC of signal intensities 
compared with the mean signal intensity of controls. Red indicates an increased level of RNA, blue 
indicates a decreased level of RNA. Each column represents a patient, and each row represents 




Figure 22. Differentially expressed miRNAs (p < 0.05) between responders and nonresponders after 
AZA treatment. The heatmap shows altered miRNA expression in AZA treated samples 
from responders and nonresponders. Color gradient intensity scale indicates logFC of miRNA signal 
intensities compared to the signal intensity of a given miRNA in a paired sample at baseline.  
Red indicates an increased level of RNA, blue indicates a decreased level of RNA. Each column 
represents a patient, and each row represents a miRNA. CR – complete remission, PR – partial 
remission, SD – stable disease, and PD – progressed disease 
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10.3.4 Quantification of individual miRNA levels by RT-qPCR 
To verify the microarray results, the levels of miR-17-3p, miR-27b-3p, miR-100-5p, miR-133b,  
and miR-142-3p were quantified in the validation cohort by RT-qPCR (Figure 23). These miRNAs were 
selected based on their significant differential expression in microarray profiling. In concordance 
with the microarray data, miR-17-3p, miR-100-5p, and miR-133b were differentially expressed 
between the responders and nonresponders. The level of miR-17-3p was significantly increased  
(p < 0.05), and the levels of miR-100-5p and miR-133b were significantly reduced (p < 0.01) 
in responders compared to nonresponders.  
Comparison of the baseline samples with those collected during AZA treatment revealed increased 
level of miR-27b-3p and decreased level of miR-142-3p (p < 0.01) during AZA treatment. Levels 
of both miRNAs during AZA treatment were approaching closer to their levels in control samples.  
 
Figure 23. Relative expression of selected miRNAs measured by RT-qPCR. CTR – controls,  
RS – responders at baseline, RS AZA – AZA treated responders, nRS – nonresponders at baseline,  
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10.3.5 Correlation of clinical parameters with miRNA levels  
Further, miR-17-3p, miR-100-5p, and miR-133b, which were significantly deregulated between 
responders and nonresponders, were tested as potential predictive biomarkers of AZA treatment 
response. Based on the ROC curve analysis, the cut-off values for miR-17-3p, miR-100-5p,  
and miR-133b were defined (Table 23) and according to them, patients were divided in ‘high-miR’ 
and ‘low-miR’ groups. A series of statistical tests were performed to compare these two groups. 
The ORR was significantly higher in patient groups with high-miR-17-3p (p < 0.05), low-miR-100-5p  
(p < 0.05), and low-miR-133b (p < 0.01) (Table 24). There were no differences in patient age, sex, 
percentage of BM blasts, cytogenetics, and diagnosis between the groups divided according  
to the levels of these miRNAs. Similarly, the number of AZA cycles, follow-up period,  
and the proportion of patients who died during this period were comparable between the groups.  
Further statistical testing examined an impact of clinical and molecular variables on the OS after AZA 
treatment initiation. Univariate analysis revealed that OS was not significantly associated with age, 
sex, percentage of BM blasts, WHO-based diagnosis, miR-17-3p or miR-133b level. The only variables 
significantly associated (p < 0.05) with OS were the IPSS-R cytogenetics and the level of miR-100-5p 
(Table 24 and Figure 24). The patients with good karyotype had significantly longer OS than those 
with unfavourable karyotype. Stratification by miR-100-5p expression showed prolonged OS  
in the low-miR-100-5p group compared to the high-miR-100-5p group. Multivariate Cox regression 
analysis confirmed that both the IPSS-R cytogenetics and the level of miR-100-5p represented 
prognostic factors for the OS (Table 25). 
 
Table 23. Cut-off values (miRNA expression fold change compared to mean miRNA level in healthy 
controls) for selected miRNAs based on ROC curve analysis. 
 
Cut-off value AUC 95 % CI 
miR-17-3p  2.0 0.641 0.427-0.855 
miR-100-5p 0.4 0.713 0.518-0.908 
miR-133b 0.6 0.715 0.509-0.921 
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Table 24. Relation of clinical and molecular variables to ORR and OS. Int – intermediate 
Variable n ORR 
n (%) 
p value OS  
median (mo.) 
p value 
Age < 70 years 15 6 (40 %) .930 19.6 .385 
≥ 70 years 12 5 (42 %) 21.2 
Sex Male 15 6 (40 %) .930 19.6 .837 
Female 12 5 (42 %) 24.9 
Blasts < 10 % 7 3 (43 %) .895 23.9 .515 
≥ 10 % 20 8 (40 %) 19.4 
Karyotype Normal 8 3 (38 %) .330 21.2 .853 
Isolated del(5q) 5 3 (56%) 25.9 
Other 13 3 (33 %) 13.0 
Cytogenetics by IPSS-R Good 17 7 (41 %) .334 25.9 .033 
Int/poor/very 
poor 
9 2 (22 %) 11.3 
Diagnosis MDS 19 8 (42 %) .824 21.1 .953 
AML-MRC 8 3 (38 %) 20.4 
miR-17-3p  Low  15 3 (20 %) .014 21.2 .215 
High  12 8 (67 %) 19.1 
miR-100-5p  Low  13 8 (62 %) .034 25.9 .047 
High  14 3 (21 %) 16.4 
miR-133b Low  9 7 (78 %) .005 19.1 .915 
High  18 4 (22 %) 22.4 
 
 
Figure 24. OS of patients stratified according to IPSS-R cytogenetics and miR-100-5p level (p < 0.05). 
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Table 25. Multivariate Cox analysis for OS. Int – intermediate, HR – hazard ratio, CI – confidence 
interval 
Variable HR 95 % CI p value 
Age (≥ 70 years) 2.540 0.795 to 8.123 .116 
Female sex 0.659 0.243 to 1.788 .413 
Blasts (≥ 10 %) 4.245 0.930 to 19.372 .062 
Cytogenetics by IPSS-R (int/poor/very poor) 10.040 2.649 to 38.058 .001 
AML-MRC diagnosis 1.289 0.474 to 3.508 .620 
High miR-100-5p 4.066 1.444 to 11.445 .008 
 
 




Because MDS are a heterogeneous group of disorders, the need to investigate further possibilities 
of the disease classification, prognosis assessment, and treatment responsiveness is still emerging. 
Since the discovery of sncRNA importance in cellular processes and disease development, there has 
been a great effort to investigate functions and relevance of these molecules in the pathophysiology 
of MDS as well. So far, mostly cellular miRNAs have been explored in MDS. Most of these studies 
associate MDS subtypes with different miRNA profiles, indicating that miRNAs are able to classify 
MDS. Concerning circulating sncRNAs in MDS, only a few studies have been performed up to now. 
However, circulating sncRNAs are of a great interest as potential novel noninvasive molecular 
biomarkers of the disease. The investigation of their profiles, functions, and regulation in plasma 
is needed to better understand their relevance and find the way of their application as biomarkers.  
Thus, we studied profiles of circulating sncRNAs in plasma (P1 and P2) in order to search 
for individual miRNAs associated with MDS, its progression and AZA therapy. Except for circulating 
sncRNAs, we also investigated miRNA profiles in BM cells exclusively focusing on specific miRNAs that 
may predict patient response to AZA therapy (P3). 
 
11.1 Publication 1  
Dostalova Merkerova et al., Microarray profiling defines circulating microRNAs associated 
with myelodysplastic syndromes, Neoplasma, 2017 
 
In our initial study, we aimed to investigate circulating miRNA profiles in total plasma of MDS 
patients and to determine specific miRNAs that could serve as disease biomarkers. In view of the fact 
that comprehensive profiling by NGS was not available to us at that time, we used a microarray 
platform that allowed an investigation of 2,006 predefined miRNAs. 
The results showed altered miRNA profiles between MDS patients and controls, and between lower-
risk and higher-risk MDS groups. Based on the expression data, we selected several haematopoiesis 
and/or oncology related miRNAs (miR-16-5p, miR-27a-3p, miR-150-5p, miR-199a-5p, miR-223-3p, 
and miR-451a) to explore their levels and association with MDS in detail. When comparing miRNA 
levels between lower-risk and higher-risk MDS groups, significantly decreased levels of miR-27a-3p, 
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miR-199a-5p, and miR-223-3p were revealed in higher-risk disease, suggesting that higher levels 
of these miRNAs are associated with favourable prognosis. Further, we evaluated prognostic values 
of these miRNAs for PFS and OS. The results showed that high level of miR-451a indicate better PFS 
and high level of miR-223-3p associates significantly with better OS.  
Because patients with different prognoses showed specific levels of plasma miRNAs, it may be 
anticipated that these miRNAs play a role in the disease progression. It was demonstrated that  
miR-27 enhances differentiation of myeloblasts via posttranscriptional downregulation of RUNX1 
(240), which is a key transcription factor in haematopoiesis (241). Level of miR-199a-5p was found 
to be significantly higher in BM of AML patients who achieved complete remission 
after chemotherapy compared to refractory/relapsed AML patients. It was demonstrated that  
miR-199a-5p represses protective autophagy of AML cells and overcomes chemoresistance 
by directly targeting damage regulator autophagy modulator 1 (DRAM1) (242). miR-451 is a positive 
regulator of erythroid cell maturation (97) and miR-223 is a key regulator of myeloid lineage (243). 
Both miR-451 and miR-223 are believed to act as tumour suppressors, and the low plasma levels 
of these miRNAs in higher-risk MDS patients may contribute to the promotion of leukaemic cell 
growth. It was shown that miR-223 blocks cell cycle progression in myeloid cells and its expression is 
suppressed in AML (244,245). Further, AML patients with significantly higher levels of miR-223 
in blasts show favourable prognosis, whereas miR-223 levels are low in patients with worse 
outcomes (246). Most recently, it has been demonstrated that miR-223 inhibits the expression 
of ribosomal protein S14 (RPS14) in all risk groups and different MDS subtypes (247). RPS14 is 
commonly deleted in del(5q) MDS (248), but its low expression was also shown to be frequently 
detected in MDS patients without 5q deletion, and is associated with prolonged survival of these 
patients (249). This evidence indicates that high level of miR-223 suppressing RPS14 may contribute 
to better survival of patients, which is in concordance with our results. Notably, we have previously 
detected overexpression of cellular miR-451 and miR-223 in CD34+ cells in MDS patients with del(5q) 
(197), further supporting our findings that high levels of miR-451 and miR-223 are associated with 
a favourable prognosis in MDS. 
There is a great interest in revealing the origin of circulating miRNAs in haematopoietic diseases. 
Pritchard et al. (250) demonstrated that blood cells are major contributors to circulating miRNAs 
and their levels are strongly influenced by changes in blood cell counts. They showed that plasma 
levels of miRNAs expressed by myeloid (e.g. miR-223, miR-227, miR-574-3p, and let-7a) and lymphoid 
(e.g. miR-150) blood cells correlate with corresponding blood cell counts (250). Further, 
Stamatopoulos et al. (189) demonstrated that high serum level of miR-150 in CLL patients is linked 
to a high lymphocyte count and cellular miR-150 level might be regulated by its release 
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from leukaemic cells into the extracellular space. However, they could not definitively prove 
the correlation between cellular and serum levels of miR-150, suggesting that it might be released by 
multiple cell types (189). We also attempted to trace the origin of circulating miRNAs. As cytopenia is 
one of the main features of MDS, we examined whether miRNAs enriched in the cytopenic lineages 
exhibit reduced levels in MDS plasma. We tested levels of miR-223, which is enriched in myeloid cells 
(250,251), miR-451a and miR-16 enriched in erythrocytes (97,250), miR-27 enriched in granulocytes 
(240), miR-150 enriched in lymphocytes (250,251), and miR-199 enriched in platelets (252). However, 
we did not observe any correlation between circulating miRNA levels and blood counts of the tested 
lineages. Furthermore, we examined the myeloblastic cell population as a source of circulating 
miRNAs in MDS. To assess the correlation between cellular and circulating miRNA levels, we used our 
previously measured data on miRNA expression profiles of CD34+ MDS cells (196), which form 
the majority of MDS myeloblasts (253). The levels of circulating miRNAs, however, did not reflect 
their levels in CD34+ cells. These results suggest that the release of miRNAs from cells is more likely 
miRNA specific, not cell specific process. This finding is in agreement with other studies reporting 
that extracellular miRNA profiles do not reflect profiles of original cells (132,254), suggesting that 
miRNAs are retained or released selectively and that cellular and extracellular miRNAs should be 
considered independently when evaluating them as disease biomarkers. 
 
11.2 Publication 2 
Hrustincova et al., Circulating small noncoding RNAs have specific patterns in plasma 
and extracellular vesicles in myelodysplastic syndromes and are predictive of patient outcome, Cells, 
2020 
 
In the most recent publication, we have performed small RNA-seq of circulating RNAs, which allowed 
us to study not only miRNAs, but also other sncRNA species present in MDS plasma. In recent years, 
investigation of circulating sncRNAs has moved from analysing of their content in total plasma 
to analyses of separated EVs. Thus, we compared circulating sncRNA profiles of paired samples from 
total plasma and EVs to find whether their sncRNA contents reflect each other or not and which 
of these two materials would be a better source of circulating sncRNA biomarkers for MDS. 
EVs are lipid bound vesicles secreted by cells into the extracellular space. They contain a cargo 
of diverse molecules and are considered to play a role in cell-to-cell communication (255), which is 
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of special scientific interest. Moreover, they appear to be more protective of RNA degradation 
compared to plasma or serum, suggesting that they may provide more reliable profile of sncRNAs 
(145). It was reported that tumour cells secrete significantly more exosomes into the tumour 
microenvironment than normal cells, leading to an increased number of exosomes in the circulatory 
system (256). Szczepanski et al. observed that serum of AML patients contained higher levels 
of microvesicles compared to that of controls (257). On the contrary, Enjeti et al. (220) found 
significantly lower levels of microvesicles in MDS plasma than in controls (220). In our study, we did 
not identify different levels of EVs between MDS and control plasma but rather noticed differences 
in their sizes, specifically an increase in EVs of larger diameters. Further, we observed a higher 
content of their RNA cargo, which is in agreement with a study of Enjeti et al. (220) determining 
doubled RNA content in EVs from MDS plasma compared to controls (220). These results indicate 
that features and content of EVs are changed in MDS and further exploration is needed. 
Importantly, we compared RNA content between total plasma and EVs. Hierarchical clustering of all 
samples based on their RNA profiles showed that the RNA content of EVs is more homogeneous than 
that of total plasma. The larger heterogeneity of RNAs in total plasma can be expected because 
plasma includes not only various EVs but also other RNA carriers, such as proteins, lipoprotein 
particles, and apoptotic bodies, whereas our isolated EV fraction contained mostly exosomes. 
The larger homogeneity of RNA content in EV samples may be promoted by a selective packaging of 
specific RNAs in EVs (132,134,146). Although the numbers of particular miRNAs and their levels 
detected in exosomes were found to be significantly lower than in plasma (258), specific miRNAs 
were found to be enriched in exosomes (258,259), indicating exosomes to be the major source 
for some circulating miRNAs. These results suggest that the contents of the two materials do not 
completely reflect one another but rather represent independent sources of RNA, which may provide 
different insights into the biological processes occurring during disease pathogenesis. 
Subsequent classification of read sequences into various RNA categories revealed additional 
differences between the two materials. Samples of total plasma had a substantially higher proportion 
of miRNA reads (60 and 46 percent of miRNA reads in total plasma and EVs, respectively) and a lower 
proportion of uncharacterized reads (33 and 48 percent of uncharacterized reads in total plasma and 
EVs, respectively). Xie et al. (258) measured miRNA levels in total plasma and exosomes and also 
found significantly higher miRNA levels in total plasma (258). It is still debated whether EVs contain 
biologically meaningful amount of miRNAs able to provide a reliable source of miRNA biomarkers. 
Chevillet et al. (260) suggested that most individual exosomes do not carry any biologically significant 
numbers of miRNAs and are, therefore, unlikely to be of physiologic relevance in miRNA-based  
cell-to-cell communication (260). A significant underrepresentation of miRNAs over other RNA 
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species in exosomes has been confirmed by other studies (259,261,262). On the contrary, there are 
studies demonstrating that exosomes provide a sufficient source of miRNAs for disease biomarker 
detection (145,263). Thus, there is still no definitive consensus on the relevance of EV-mediated  
cell-to-cell communication and further investigation is needed. 
One of the most interesting findings of this study was the discovery that RNA profiles of paired total 
plasma and EV samples substantially differed in MDS patients, whereas they remained closely similar 
in healthy individuals. The number of deregulated sncRNAs between paired samples of total plasma 
and EVs was almost ten-fold higher in MDS compared to controls. Such a great increase suggests that 
regulation and mechanisms of sncRNA release into the blood circulation are specifically affected 
in MDS, changing sncRNA profile as a whole. In agreement with our observation, Xie et al. (258) 
found deregulated miRNA levels between plasma and exosomes in animal models with kidney 
disease (258), whereas no significant differences in miRNA profiles between plasma and exosomes 
were found in healthy people (264). Therefore, it seems that the release of sncRNAs into blood 
circulation is specifically affected under various pathological conditions. As a result, these changes 
may affect cell-to-cell communication of blood cells, potentially contributing to ineffective 
haematopoiesis and disease progression. 
Regarding other sncRNA species, such as piRNAs and tRNAs, we noticed an interesting pattern 
in their levels in total plasma and EVs. Whereas differentially represented miRNAs between total 
plasma and EVs were equally increased and decreased in the two materials, other sncRNA species 
were almost exclusively increased in plasma compared to EVs. Several studies demonstrated that 
different sncRNA species are preferentially loaded into different types of carriers (140,262). 
Moreover, packaging of RNA molecules within individual RNA species into carriers seems to be 
selective, i.e. specific RNA molecules are preffered to the others (258,265). Thus, sncRNA release 
appears to be thoroughly regulated process. 
To characterize the profile of circulating sncRNAs specific for MDS, we compared sncRNA levels 
of MDS samples with those of AML-MRC and control samples. We found hundreds of differentially 
represented sncRNAs between MDS and control samples in both total plasma and EVs, indicating 
molecular changes related to the disease. However, we found almost no significant differences 
in sncRNA profiles between MDS and AML-MRC samples. It has been emphasized that MDS should 
not be considered as an early phase of AML as there are biological and clinical differences between 
them (266). Still, MDS and AML share important signatures at the molecular level in terms 
of signalling pathways and genetic markers (267,268). In MDS and AML-MRC, which share 
myelodysplasia-related features, we observed similar molecular characteristics described here 
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and in our preceding paper (196). The link between MDS and AML-MRC may enable the application 
of similar therapeutic approaches that specifically address both of these clinical entities. 
Further, we investigated changes in levels of individual miRNAs between MDS and controls 
and observed that the majority of the deregulated miRNAs were increased in MDS in both, total 
plasma and EVs. Among these miRNAs, we found many miRNAs whose intracellular deregulation has 
been already associated with various haematopoietic disorders, including MDS, such as miR-34a, 
miR-125a, miR-99b, miR-10a, miR-221, miR-222, miR-223, miR-29a, and miR-150 (57,193). Although 
the roles of circulating miRNAs and the impact of their deregulation on (patho)physiological 
processes are still unclear, there is convincing evidence of their intracellular regulatory functions 
in haematopoiesis and disease development. Altogether, it appears that these circulating sncRNAs 
may affect recipient cells and contribute to the development of myelodysplasia. 
To obtain an additional look at biological functions that may be affected by deregulated miRNAs 
in MDS, we performed a miRNA target prediction and pathway enrichment analyses. Although 
different miRNAs were deregulated in total plasma versus EVs, considerable similarities  
in the affected pathways were observed, pointing to the shared targets of different miRNAs. Several 
signalling pathways associated with cancer and pluripotency of stem cells were identified 
as potentially targeted by the deregulated miRNAs (i.e. the Ras, TGF-β, and ErbB pathways). 
Furthermore, the deregulated miRNAs were also associated with pathways related  
to the extracellular environment and cell interactions (ECM-receptor interactions, focal adhesion, 
and proteoglycans in cancer). Extracellular matrix (ECM) is a complex network of extracellular 
macromolecules that provides support for surrounding cells. Specific interactions between cells 
and the ECM are mediated by transmembrane and cell-surface-associated components, leading 
to the control of different cellular activities, such as adhesion, migration, differentiation, 
proliferation, and apoptosis. Proteoglycans have been shown to be key macromolecules that 
contribute to the biology of various types of cancers through the abovementioned processes (269). 
Exosomes can also be considered integral components of the ECM since they modulate the assembly 
of the molecular network and signalling through the ECM (270). The pathway analysis thus suggest 
that the miRNAs released into blood circulation in MDS patients may further potentiate 
dysregulation of biological processes in the extracellular environment. The miRNAs may even act as 
a kind of regulatory loop affecting the functionality of EVs themselves and/or facilitating changes 
in the haematopoietic niche microenvironment. 
Somatic mutations in multiple genes have been recently described in MDS and are rapidly becoming 
the most frequently discussed aberrations associated with MDS (8). The most frequently mutated 
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genes in our patient cohort were SF3B1 and DNMT3A. Therefore, we investigated the association 
between mutational status of these genes and the levels of circulating sncRNAs. Only low numbers 
of circulating sncRNAs, however, were significantly associated with the mutational status of SF3B1 
or DNMT3A genes. This raises the question of whether the effects of a somatic mutation in a single 
gene on deregulation of circulating sncRNA levels are either negligible or whether the analysis was 
affected by a bias. Regarding possible bias, a low number of patients with detected mutations were 
analysed. Moreover, the data were undoubtedly influenced by substantial heterogeneity on multiple 
levels (i.e., additional presence of various cytogenetic aberrations that are more penetrant, 
differences in variant allele frequencies, cooccurrence of several mutations in a single patient,  
or a wide spectrum of variants in one gene that may differentially influence protein activity). Taken 
together, we observed only slight trends in deregulation of sncRNA levels, suggesting that there is no 
fundamental association between mutational status of SF3B1 or DNMT3A and levels of circulating 
sncRNAs. However, with respect to possible significant bias, further investigations would be 
beneficial. 
We also evaluated circulating sncRNAs as potential biomarkers of MDS. To define the sncRNAs that 
are associated with MDS progression and are able to predict the outcome of MDS patients,  
we compared sncRNA profiles between early and advanced MDS. Interestingly, in both plasma 
and EVs, 80 percent of the total amount of deregulated sncRNAs were increased in early MDS 
compared to advanced MDS. Among these we identified many miRNAs from a large cluster located 
within the 14q32 locus, e.g. miR-127-3p, miR-154-5p, and miR-323b-3p. These miRNAs are frequently 
altered in various cancers, and their deregulation has been linked to abnormal induction of apoptosis 
and suppression of proliferation. They are also involved in HSC differentiation (271). Interestingly,  
an in vitro study showed that miRNAs from 14q32 locus are selectively and massively released 
via exosomes, whereas they are nearly undetectable in lymphoblastoid B-cell lines (272). Moreover, 
their levels were reported to be stable in serum of healthy individuals in the course of longitudinal 
study and able to discriminate between healthy individuals and those who had been diagnosed 
with cancer over the study period (273). In MDS, the upregulation of miRNAs within the 14q32 locus 
was reported by several studies (197,274,275). In our study (276), we observed increased expression 
of 14q32 miRNAs in CD34+ cells in advanced stages of MDS and in AML-MRC and this elevation was 
associated with poor outcome. Moreover, the increased intracellular levels of 14q32 miRNAs were 
reduced after AZA treatment (276). Altogether with our current data showing the upregulation 
of miRNAs from 14q32 locus in early MDS plasma, it could be suggested that the levels of 14q32 
miRNAs have opposite trends in HSCs and in plasma in different stages of MDS. These miRNAs seem 
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to be released into the extracellular environment in early proapoptotic stages of MDS but appear 
to be retained intrinsically along with the disease progression. 
Besides association of some miRNAs with MDS progression, we intended to identify the sncRNA 
biomarkers with the highest predictive values of patient outcome throughout various sncRNA species 
circulating in MDS patient blood. Therefore, we performed additional series of bioinformatic analyses 
of RNA-seq data with regard to the survival of MDS patients and their response to AZA therapy. 
At the level of individual molecules, we identified several sncRNAs whose levels were strongly 
associated with OS of MDS patients in both total plasma and EVs. However, we almost completely 
failed to predict the response to AZA therapy. The predictive value of circulating sncRNAs 
for prediction of both patient survival and response to the therapy was substantially increased by 
the generation of combined panels of specific sncRNAs. More importantly, multivariate analysis 
proved that the combined sncRNA panel for EV samples was associated with patient OS more 
significantly than the clinical variables typically used for routine MDS diagnostics, which clearly points 
to the considerable potential of sncRNA applicability for better stratification of MDS patients.  
In addition to miRNAs, we identified a large set of other sncRNA species deregulated in our MDS 
cohort. To date, only two studies on MDS addressing intracellular non-miRNA sncRNA species have 
emerged demonstrating the utilization of tsRNAs from BM samples as predictive biomarkers 
of response to therapy and progression to AML (202,214). However, little is known about non-miRNA 
sncRNA species in blood circulation. Savelyeva et al. (277) reported that also snRNAs and snoRNAs 
represent prominent sncRNA species as promising circulating biomarkers of disease (277). Yet, in our 
results, mostly miRNAs were represented among sncRNAs with the highest predictive values 
for patient outcome. Therefore, utilizing miRNAs as possible biomarkers seems to be the most 
meaningful approach under the present circumstances. Further exploration of other sncRNA species 
is essential to represent real conditions and to bring new insights into sncRNA functions in health 
and disease. 
Altogether, all the evidence suggests the considerable potential of circulating sncRNAs to become 
auxiliary noninvasive biomarkers in MDS prognostication. However, further validation of the data 
on larger independent patient cohorts is necessary before application of sncRNA biomarkers 
into routine clinical practice. 
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11.3 Publication 3 
Krejcik et al., MicroRNA profiles as predictive markers of response to azacitidine therapy 
in myelodysplastic syndromes and acute myeloid leukaemia, Cancer Biomarkers, 2018 
 
Besides studies on circulating sncRNAs, we also focused on cellular miRNAs as predictive biomarkers 
of AZA treatment response. Despite the fact that AZA therapy improves clinical outcomes of patients 
with advanced MDS (37,38), the ORR is only between 40 to 50 percent (42,43). Therefore, 
the identification of biomarkers predictive of AZA treatment response would greatly contribute 
to individualized therapy and avoidance of therapy-related burden. 
There is an increasing number of studies focusing on search for predicitve biomarkers of response 
to AZA therapy. A variety of clinical features and molecular markers have been identified 
as potentially predictive of AZA treatment response. For example, factors such as lower haemoglobin 
level, low platelet count (278), absence of aberrant myeloid progenitors (279), mRNA expression 
of PARP1 (280), GATA1, and FLI1 (281) in BM, and mutational status of SF3B1, SETBP1, NPM1, RUNX1 
(282), TET2 (283,284), and U2AF1 (278) were reported to predict either favourable or poor response 
to AZA therapy in MDS. However, existing results are highly inconsistent and favourable response 
rates do not often associate with improved OS (285). Thus, further search for biomarkers predictive 
of AZA therapy response is needed. 
In this publication, we analysed changes in miRNA profiles of BM CD34+ cells from higher-risk MDS 
and AML-MRC patients treated with AZA. We aimed to determine miRNA profiles associated 
with therapy response and to find miRNA biomarkers that could predict response to AZA therapy. 
For this purpose, we utilized the same microarray platform as in P1, which allowed an investigation 
of 2,006 predefined miRNAs. 
The data from miRNA expression profiling demonstrated distinct miRNA profiles at baseline  
(i.e. in samples before AZA administration) between patients who later achieved a response to AZA 
therapy (responders) and patients who exhibited stable disease (SD) or progressed disease (SD) 
after AZA therapy (patients with SD and PD were considered nonresponders). As expected, miRNA 
profiles of patients with SD and PD did not exhibit significant differences and clustered together. 
With respect to this finding and the limited number of patients in the study, we performed 
subsequent analyses on the two groups, responders and nonresponders. 
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We focused on individual miRNAs with deregulated levels at baseline between later responders 
and nonresponders and found that the patients with upregulated miR-17-3p and downregulated 
miR-100-5p and miR-133b achieved a response to AZA more often. Moreover, low level  
of miR-100-5p associated with favourable OS of the AZA treated patients. miR-100 has been reported 
to act as an tumour suppressor and its reduction has been found in solid tumours (286–288). 
The upregulation of miR-100, however, has been observed in AML (289–291), indicating that it may 
act differently in various cancers. In haematopoiesis, the upregulation of miR-100 was found to arrest 
granulocyte and monocyte differentiation and promote cell survival (289). Increased level of miR-100 
is associated with advanced clinical features (290) and unfavourable karyotypes (291) of pediatric 
AML patients and predicts shorter relapse-free survival and OS (290). The upregulation of miR-100 
was also observed in AML cell lines (291). The direct target of miR-100 is ATM transcript (291), whose 
protein product is a protein kinase that acts upstream of p53 and responds to DNA damage (292). 
Overexpression of ATM protein in vitro suppresses cell viability and induces cell apoptosis. miR-100 
downregulates ATM expression leading to inhibition of cell apoptosis and increased AML cell viability  
(291). Taken together, the data indicate that upregulated miR-100 is associated with worse prognosis 
and may play an important role in the development of AML. Based on this evidence and our results, 
we propose that the decreased level of miR-100 detected in MDS/AML-MRC patients who later 
responded to AZA treatment may reflect lower aggressiveness of the disease and may be associated 
with better responsiveness to AZA therapy and patient survival.  
Among the miRNAs deregulated between AZA responders and nonresponders at baseline,  
we identified other miRNAs that are implicated in cell proliferation and oncogenesis. For example, 
miR-1 and miR-133b showed increased levels in nonresponders. These miRNAs are encoded 
in homologous clusters of miR-1/133a and miR-206/133b (293). Although miR-1 is downregulated 
in many tumours (293), its overexpression was detected in AML (294,295) in which it promotes cell 
proliferation, suggesting that it may act as an oncogene in haematologic malignancies (295). 
The HOX-related miRNAs (296), miR-10a and miR-10b, showed decreased levels in nonresponders 
and increased levels in responders. It has been shown that these miRNAs are aberrantly expressed 
in myeloid malignancies (196,297,298) and high baseline expression of the miR-10 family 
in untreated AML patients is associated with complete remission in response to induction 
chemotherapy (196). 
In the final part of this study, we determined miRNAs with changed levels after AZA therapy 
compared to their levels at baseline, indicating that they might be modulated by AZA exposure. 
Among them, numerous haematopoiesis and oncology related miRNAs, such as let-7f, miR-10,  
miR-15, and miR-181 families, were found. For example, the expression of miR-181 family members 
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was significantly reduced after the therapy. miR-181 family plays an important role in the regulation 
of haematopoiesis, including proliferation and differentiation of HSPCs and megakaryocytic lineage 
development (299). Increased expression of miR-181 family members was previously detected 
in higher-risk MDS (195), in MDS patients who later transformed to AML (202), and M1 and M2 
subtypes of AML (300). The reduction in the level of miR-181 may therefore be one  
of the downstream effects of the treatment with AZA, modulating the aberrant proliferation 
and differentiation in myeloid disorders.  
With respect to response status, we identified that the level of miR-199a-3p was exclusively 
decreased in responders after AZA therapy. Interestingly, our results (P2) also determined this 
miRNA to be one of the most common sncRNAs with the best cumulative predictive values of AZA 
treatment in total plasma. Increased level of miR-199a-3p was demonstrated to enhance 
proliferation of myeloid progenitor cells and cause AML in a preleukaemic mouse model (301), 
indicating its oncogenic role in myeloid disorders. Decreased level of miR-199-3p exclusively 
in responders after the therapy suggests that AZA may contribute to the improved patient outcome 
via downregulating the expression of miR-199a-3p. 
To conclude, our data indicate that AZA responders and nonresponders show distinct miRNA profiles 
and that specific miRNA levels before therapy initiation may predict the efficacy of AZA therapy.  
  




In this thesis, we focused on profiling of extracellular (total plasma and EVs) and intracellular (CD34+ 
BM cells) sncRNAs in MDS. In general, our results indicate that sncRNA profiles measured in both 
plasma and BM samples are specific to different stages of the disease and may predict patient 
outcomes. We identified several miRNAs and other sncRNAs that are associated with the disease 
development and may be considered as potential novel biomarkers of MDS progression 
or responsiveness to the treatment. Moreover, the sncRNA profiling performed on MDS plasma 
provides new information on the phenomenon of circulating miRNAs in MDS pathophysiology. 
One of the important aims of this study was to compare sncRNA profiles in different materials 
and to define which of them would be more suitable for monitoring of MDS biomarkers. Our results 
show specific sncRNA profiles to CD34+ BM cells, total plasma, and EVs. Thus, it appears that each 
material as a source of sncRNAs provide different point of view on the actual condition 
of an organism. Nowadays, BM cells are considered the most meaningful source of MDS biomarkers. 
The necessity of BM biopsy, however, leads to an effort to find less invasively accessible source 
of biomarkers, such as blood plasma. Hornick et al. (181) proposed that exosome miRNAs may serve 
as biomarkers for early detection of AML recurrence as exosomes derived from aberrant blasts can 
be detected in blood circulation earlier than the blasts themselves. In addition, they indicated that 
AML exosomes reflect contributions from both leukaemic blasts and marrow stromal cells modified 
by the presence of the malignancy and suggested them to be the first potential leukaemia biomarker 
representing multiple components of the malignant microenvironment (181).  
Remarkably, our results indicate that the two extracellular materials, total plasma and EVs, do not 
show the same sncRNA profiles. It is in agreement with the findings that sncRNAs are released 
from cells selectively in different ways. A study that compared miRNA content in total plasma 
and plasma-derived exosomes in kidney disease (258) showed that miRNAs in plasma and 
in exosomes are differentially regulated and thus, the measurement of exosomal miRNAs cannot be 
replaced by the measurement of miRNAs in plasma, or vice versa (258). It remains to be elucidated 
which of the materials would be most useful in particular circumstances. Based on our results, EVs 
seem to be a better source of sncRNA biomarkers for patient survival, whereas sncRNAs circulating 
in total plasma might be predictive of AZA treatment response. 
Regarding biomarkers predictive of response to AZA treatment, our results show that BM cells 
and total plasma may be useful sources. In both materials, we identified specific miRNAs that show 
potential to predict the therapy response. The specific miRNAs were different between BM cells and 
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total plasma except for miR-199a-3p, which was identified as a predictive biomarker in both 
materials. Importantly, the predictive value of circulating miRNAs substantially increased when 
the predictive score was generated from the data of multiple miRNAs. Further investigation 
of expression and functions of these miRNAs (particularly of miR-199a-3p) would clarify 
the significance of their ability to predict the response to AZA therapy. 
Along with MDS progression, sncRNA profiles change, showing alterations at the levels of many 
haematopoiesis-related miRNAs as well as other sncRNA species. It remains to be clarified whether 
changes in circulating sncRNA levels are a consequence of deregulated sncRNA release from cells 
related to a disease without any specific function, when its impact on recipient cells would be just 
an accident, or if there is a purpose of affecting specific recipient cells in a particular way. Notably, 
the effects of sncRNAs taken up by recipient cells may lead either towards improvement of disease 
outcome or disease progression. It may be influenced by the origin of particular EVs, i.e. whether 
they are derived from the normal or the aberrant cells. It has been shown that tumour cells secrete 
often increased amount of exosomes than normal cells, carrying molecules specific to the tumour 
cells from which the EVs were derived (302). EVs in haematologic malignancies have been reported 
to modify malignant cells themselves and also cells of BM microenvironment, making 
the microenvironment more supportive of malignancy, suppressing the immune system, 
and inducing drug resistance (303). For example, Hornick et al. (155) observed that a unique miRNA 
profile of exosomes released from AML cells has the potential to increase leukaemic fitness 
by dysregulating other cell types (155). Based on this evidence, it appears that EVs may be implicated 
in disease development and progression. 
With the increasing evidence of EV-mediated intercellular communication, their ability to alter 
the functions of recipient cells, and their role in disease development and progression, EVs have 
become considered as novel therapeutic targets. The strategy is to inhibit aberrant cell 
communication via EVs to prevent their growth and spread.  Different approaches can be applied,  
i.e. interfering with EV biogenesis and release from cells, blocking EV uptake by recipient cells,  
and removing of EVs from the circulation (303,304). Further, EVs have potential to be utilized 
for therapeutic purposes in terms of both drug delivery and regenerative medicine. They have 
natural features that make them suitable therapeutic vehicles, such as natural stability in body fluids, 
protection of their cargo from degradation, inherent targeting ability, low immunogenicity, 
and finally, the possibility of engineering them (303,305,306). However, despite of recent advances, 
in order to effectively utilize EVs as therapeutic targets and tools, it would be highly appropriate 
to improve the understanding of their biology and become fully aware of the intricacy of the targeted 
therapy application. 
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To conclude, our data provide not only a rationale for the potential clinically effective application 
of circulating sncRNAs as prognostic and predictive biomarkers of MDS but also raise new intriguing 
questions about the pathobiology of release mechanisms and possible consequences of their defects 
in haematopoietic disorders. Further investigations on sncRNA function, role in cell-to-cell 
communication, and their release dynamics in health and disease conditions are still needed to gain 
better insight and draw meaningful application of sncRNAs in diagnostics, prognostics and prediction 
of treatment response in MDS. 
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